

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 16/00, 16/40, G01N 33/53, C07H 21/02, 21/04, A61K 39/395		A1	(11) International Publication Number: WO 99/57153 (43) International Publication Date: 11 November 1999 (11.11.99)
(21) International Application Number: PCT/US99/09255 (22) International Filing Date: 29 April 1999 (29.04.99) (30) Priority Data: 09/071,739 1 May 1998 (01.05.98) US (71) Applicants (for all designated States except US): INSIGHT STRATEGY & MARKETING LTD. [IL/IL]; Kiryat Weizman Science Park, P.O. Box 2128, 76121 Rehovot (IL). HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. [IL/IL]; Kiryat Hadassah, P.O. Box 12000, 91120 Jerusalem (IL). (71) Applicant (for TJ only): FRIEDMAN, Mark, M. [US/IL]; 1 Alharizi, 43406 Raanana (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): PECKER, Iris [IL/IL]; Wolfson Street 42, 75203 Rishon Le Zion (IL). VLODAVSKY, Israel [IL/IL]; Arbel Street 34, 90805 Mevaseret Zion (IL). FRIEDMAN, Yael [IL/IL]; Aluf Shimon Street 3, 92504 Jerusalem (IL). PERETS, Tuvia [IL/IL]; Hamavdil Street 12, 52562 Ramat Gan (IL).		(74) Common Representative: FRIEDMAN, Mark, M.; c/o Castorina, Antony, Suite 207, 2001 Jefferson Davis Highway, Arlington, VA 22202 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: HEPARANASE SPECIFIC MOLECULAR PROBES AND THEIR USE IN RESEARCH AND MEDICAL APPLICATIONS			
(57) Abstract A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HEPARANASE SPECIFIC MOLECULAR PROBES AND THEIR USE IN RESEARCH AND MEDICAL APPLICATIONS

FIELD AND BACKGROUND OF THE INVENTION

5 The present invention relates to heparanase specific molecular probes
their use in research and medical applications. More particularly, the
present invention relates to the use of heparanase specific molecular probes,
such as anti-heparanase antibodies (both poly- and monoclonal) and
heparanase gene (*hpa*) derived nucleic acids, including, but not limited to,
10 PCR primers, antisense oligonucleotide probes, antisense RNA probes,
DNA probes and the like for detection and monitoring of malignancies,
metastasis and other non-malignant conditions, efficiency of therapeutic
treatments, targeted drug delivery and therapy.

Heparan sulfate proteoglycans (HSPGs): HSPGs are ubiquitous
15 macromolecules associated with the cell surface and extracellular matrix
(ECM) of a wide range of cells of vertebrate and invertebrate tissues (1-5).
The basic HSPG structure consists of a protein core to which several linear
heparan sulfate chains are covalently attached. The polysaccharide chains
are typically composed of repeating hexuronic and D-glucosamine
20 disaccharide units that are substituted to a varying extent with N- and O-
linked sulfate moieties and N-linked acetyl groups (1-5). Studies on the
involvement of ECM molecules in cell attachment, growth and
differentiation revealed a central role of HSPGs in embryonic
morphogenesis, angiogenesis, metastasis, neurite outgrowth and tissue
25 repair (1-5). The heparan sulfate (HS) chains, unique in their ability to bind
a multitude of proteins, ensure that a wide variety of effector molecules
cling to the cell surface (4-6). HSPGs are also prominent components of
blood vessels (3). In large vessels they are concentrated mostly in the
intima and inner media, whereas in capillaries they are found mainly in the
30 subendothelial basement membrane where they support proliferating and
migrating endothelial cells and stabilize the structure of the capillary wall.
The ability of HSPGs to interact with ECM macromolecules such as
collagen, laminin and fibronectin, and with different attachment sites on
plasma membranes suggests a key role for this proteoglycan in the self-
35 assembly and insolubility of ECM components, as well as in cell adhesion
and locomotion. Cleavage of HS may therefore result in disassembly of the
subendothelial ECM and hence may play a decisive role in extravasation of
blood-borne cells (7-9). HS catabolism is observed in inflammation, wound

repair, diabetes, and cancer metastasis, suggesting that enzymes which degrade HS play important roles in pathologic processes.

Involvement of heparanase in tumor cell invasion and metastasis:

Circulating tumor cells arrested in the capillary beds of different organs must invade the endothelial cell lining and degrade its underlying basement membrane (BM) in order to escape into the extravascular tissue(s) where they establish metastasis (10). Several cellular enzymes (e.g., collagenase IV, plasminogen activator, cathepsin B, elastase) are thought to be involved in degradation of the BM (10). Among these enzymes is an endo- β -D-glucuronidase (heparanase) that cleaves HS at specific intrachain sites (7, 9, 11-12). Expression of a HS degrading heparanase was found to correlate with the metastatic potential of mouse lymphoma (11), fibrosarcoma and melanoma (9) cells. Treatment of experimental animals with heparanase inhibitors (i.e. non-anticoagulant species of low MW heparin) markedly reduced (>90%) the incidence of lung metastases induced by B16 melanoma, Lewis lung carcinoma and mammary adenocarcinoma cells (8, 9, 13).

Heparanase activity could not be detected in normal stromal fibroblasts, mesothelial, endothelial and smooth muscle cells derived from non cancerous biopsies and effusions (12). These observations indicate that heparanase expression may serve as a marker for tumor cells and in particular for those which are highly invasive or potentially invasive. If the same conclusion can be reached by immunostaining of tissue specimens, anti-heparanase antibodies may be applied for early detection and diagnosis of metastatic cell populations and micro-metastases.

Our studies on the control of tumor progression by its local environment, focus on the interaction of cells with the extracellular matrix (ECM) produced by cultured corneal and vascular endothelial cells (EC) (14, 15). This ECM closely resembles the subendothelium *in vivo* in its morphological appearance and molecular composition. It contains collagens (mostly type III and IV, with smaller amounts of types I and V), proteoglycans (mostly heparan sulfate- and dermatan sulfate- proteoglycans, with smaller amounts of chondroitin sulfate proteoglycans), laminin, fibronectin, entactin and elastin (13, 14). The ability of cells to degrade HS in the ECM was studied by allowing cells to interact with a metabolically sulfate labeled ECM, followed by gel filtration (Sephacrose 6B) analysis of degradation products released into the culture medium (11). While intact HSPG are eluted next to the void volume of the column ($K_{av} < 0.2$, $M_r \sim$

0.5x10⁶), labeled degradation fragments of HS side chains are eluted more toward the V_t of the column (0.5 < k_{av} < 0.8, M_r = 5-7x10³) (11).

Possible involvement of heparanase in tumor angiogenesis:

Fibroblast growth factors are a family of structurally related polypeptides characterized by high affinity to heparin (16). They are highly mitogenic for vascular endothelial cells (EC) and are among the most potent inducers of neovascularization (16, 17). Basic fibroblast growth factor (bFGF) has been extracted from subendothelial ECM produced *in vitro* and from BM of the cornea, suggesting that ECM may serve as a reservoir for bFGF (18). Studies on the interaction of bFGF with ECM revealed that bFGF binds to HSPG in the ECM and can be released in an active form by HS degrading enzymes (19, 20). Heparanase activity expressed by platelets, mast cells, neutrophils, and lymphoma cells releases active bFGF from ECM and BM (20), suggesting that heparanase may not only function in cell migration and invasion, but may also elicit an indirect neovascular response (18). These results suggest that the ECM HSPGs provide a natural storage depot for bFGF and possibly other heparin-binding growth promoting factors. Displacement of bFGF from its storage within ECM may therefore provide a novel mechanism for induction of neovascularization in normal and pathological situations (6, 18).

Seeking for metastases by detecting cancer biomarkers: Detecting and monitoring cancer metastases - once thought to be an almost impossible task - appears to be moving toward the realm of the practical. The results of research presented at the recent Annual Meeting of the American Association for Cancer Research and the American Society of Clinical Oncology identified two approaches for detecting the onset of cancer metastases.

(i) Quantifying the levels of two cytokines - vascular endothelial growth factor and basic fibroblast growth factor - that are involved in the angiogenesis process which is critical to tumor metastases. Researchers have found elevated levels of both cytokines in the serum and urine of people with renal cell carcinoma and non-small cell lung cancer (17).

(ii) Cell isolation and nucleic acid amplification methods that have been used to detect circulating tumor cells in the peripheral blood of patients with melanoma and prostate, ovarian, colon and breast cancers.

The clinical utility of these tests in monitoring tumor cells in the circulatory system or detecting critical factors in the process of angiogenesis has been shown to be feasible. These tests can help predict patient

outcome, monitor patient response to therapy and guide the selection of therapy. Several of these tests offer the additional benefits of being fairly rapid to perform and minimally invasive.

For example, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were measured in pre- and post-operative samples and sera of untreated and treated metastatic patients by using the quantitative sandwich EIA quantikine from R&D Systems. The majority of patients with metastatic solid tumors had elevated serum levels of both cytokines, the type of tumor was not exclusive of either factor, and elevated levels returned to normal after chemotherapy or surgery.

Another example is serum concentration of soluble Cytokeratin Fragment 19 as a prognostic factor of non-small cell lung cancer. Archived sera of 79 lung cancer patients was tested for CK19 using Boehringer Mannheim ELISA. Serum concentration correlated with squamous cell carcinoma antigen, and the survival period was found to be longer in patients with normal CK19 serum level.

Expression of heparanase by cells of the immune system: Heparanase activity correlates with the ability of activated cells of the immune system to leave the circulation and elicit both inflammatory and autoimmune responses. Interaction of platelets, granulocytes, T and B lymphocytes, macrophages and mast cells with the subendothelial ECM is associated with degradation of heparan sulfate (HS) by heparanase activity (7). The enzyme is released from intracellular compartments (e.g., lysosomes, specific granules) in response to various activation signals (e.g., thrombin, calcium ionophore, immune complexes, antigens, mitogens), suggesting its regulated involvement and presence in inflammatory sites and autoimmune lesions. Heparan sulfate degrading enzymes released by platelets and macrophages are likely to be present in atherosclerotic lesions (21). Hence, cDNA probes and anti-heparanase antibodies may be applied for detection and early diagnosis of these lesions.

Cloning and expression of the heparanase gene: The cloning and expression of the human heparanase gene are described in U.S. Pat. application No. 08/922,170, which is incorporated by reference as if fully set forth herein. A purified fraction of heparanase isolated from human hepatoma cells was subjected to tryptic digestion. Peptides were separated by high pressure liquid chromatography and micro sequenced. The sequence of one of the peptides was used to screen data bases for homology to the corresponding back translated DNA sequence. This procedure led to

the identification of a clone containing an insert of 1020 base pairs (bp) which included an open reading frame of 963 bp followed by 27 bp of 3' untranslated region and a Poly A tail. The new gene was designated *hpa*. Cloning of the missing 5' end of *hpa* cDNA was performed by PCR amplification of DNA from placenta cDNA composite. The plasmid containing the entire heparanase cDNA was designated *phpa*. The joined cDNA fragment contained an open reading frame which encodes a polypeptide of 543 amino acids with a calculated molecular weight (MW) of 61,192 daltons. The ability of the *hpa* gene product to catalyze degradation of heparan sulfate (HS) *in vitro* was examined by expressing the entire open reading frame of *hpa* in High five and Sf21 insect cells, using the Baculovirus expression system. Extracts of infected cells were assayed for heparanase activity. For this purpose, cell lysates were incubated with sulfate labeled, ECM-derived HSPG (peak I), followed by gel filtration analysis (Sephacrose 6B) of the reaction mixture. While the substrate alone consisted of high molecular weight (MW) material, incubation of the HSPG substrate with lysates of cells infected with *hpa* containing virus resulted in a complete conversion of the high MW substrate into low MW labeled heparan sulfate degradation fragments.

In subsequent experiments, the labeled HSPG substrate was incubated with the culture medium of infected High Five and Sf21 cells. Heparanase activity, reflected by the conversion of the high MW HSPG substrate into low MW HS degradation fragments, was found in the culture medium of cells infected with the *pFhpa* virus, but not the control *pF1* virus. Altogether, these results indicate that the heparanase enzyme is expressed in an active form by cells infected with Baculovirus containing the newly identified human *hpa* gene. In other experiments, we have demonstrated that the heparanase enzyme expressed by cells infected with the *pFhpa* virus is capable of degrading HS complexed to other macromolecular constituents (e.g., fibronectin, laminin, collagen) present in a naturally produced intact ECM, in a manner similar to that reported for highly metastatic tumor cells or activated cells of the immune system.

Purification of the recombinant heparanase enzyme: The purification of the human heparanase gene are described in U.S. Pat. application No. 08/922,170, which is incorporated by reference as if fully set forth herein. Sf21 insect cells were infected with *pFhpa* virus and the culture medium was applied onto a heparin-Sepharose column. Fractions were eluted with a salt gradient (0.35-2 M NaCl) and tested for heparanase

activity and protein profile (SDS/PAGE followed by silver staining). Heparanase activity correlated with the appearance of a protein band of about 63 kDa in fractions 19-24, consistent with the expected MW of the *hpa* gene product. Active fractions eluted from heparin-Sepharose were
5 pooled, concentrated and applied onto a Superdex 75 FPLC gel filtration column. Aliquots of each fraction were tested for heparanase activity and protein profile. A correlation was found between the appearance of a major protein of about 63 kDa in fractions 4-7 and heparanase activity. This protein was not present in medium conditioned by control non-infected Sf21
10 cells and subjected to the same purification protocol.

Research on the involvement of heparanase/HS in tumor cell metastasis and angiogenesis has been handicapped by the lack of biological tools (i.e., molecular probes, antibodies) to explore a causative role of heparanase in disease. U.S. Pat. application 08/922,170 offers, for the
15 first time, a good opportunity to elucidate the enzyme's involvement in tumor metastasis and angiogenesis and the related diagnostic applications.

On the basis of the examples described below, it appears that cDNA and RNA probes, PCR primers, and anti-heparanase antibodies (heparanase specific molecular probes) can be applied to detect the heparanase gene and
20 protein and hence for early diagnosis of micrometastases, autoimmune lesions, renal failure and atherosclerotic lesions using biopsy specimens, plasma samples, and body fluids.

Specificity and advantages over other reported antibodies: A variety of blood, tumor cells and certain normal cells have been shown to
25 produce significant amounts of heparanase activity. The purification to homogeneity and characterization of mammalian heparanases has been difficult, primarily due to the lack of a convenient assay. Most reports contain only partial description with conflicting information. Oosta, et al. (22) described the purification of a human platelet heparanase with an
30 estimated molecular mass of 134 kDa expressing an endoglucuronidase activity. Hoogewert, et al. (23) reported the purification of a 30 kDa human platelet heparanase which was shown to be an endoglucosaminidase that cleave both heparin and heparan sulfate essentially to disaccharides. They claimed that the holoenzyme consists of four subunits, each closely related
35 to the CXC chemokines CTAPIII, NAP-2 and β -thromboglobulin (23). Freeman and Parish (24) have purified to homogeneity a 50 kDa platelet heparanase exhibiting endoglucuronidase activity. Likewise heparanase enzyme purified from human placenta and from hepatoma cell line (U.S.

Pat. No. 5,362,641) had a molecular mass of approximately 48 kDa. A similar molecular weight was determined by gel filtration analysis of partially purified heparanase enzymes isolated from human platelets, human neutrophils and mouse B16 melanoma cells (our unpublished data). In contrast, heparanase purified from B16 melanoma cells by Nakajima, et al. (9, 26) had a molecular weight of 96 kDa. The latter enzyme has been localized immunochemically to the cell surface and cytoplasm of human melanoma lesions using a polyclonal antiserum (26) and in tertiary granules in neutrophils using monoclonal antibodies (26a), both directed against a putative amino terminal sequence from purified B16F10 melanoma cell heparanase (26). However, the melanoma heparanase amino terminal sequence was found to be characteristic of a 94 kDa glucose-regulated protein (GRP94/endoplasmic reticulum protein) that functions as a molecular chaperone which lacks heparanase activity (27). This result and a recent study using anti-endoplasmic reticulum protein antibody (28) suggest that the endoplasmic reticulum-like 98 kDa protein found in purified melanoma heparanase preparations is a contaminant (27, 28). This calls into question the previous heparanase immunolocalization studies carried out using the B16 melanoma heparanase amino terminal peptide antiserum (26). Likewise, antiserum directed against the amino terminal sequence of CTAP III was applied to immunolocalize the heparanase enzyme in biopsy specimens of human prostate and breast carcinomas (29, 30). Again, the validity of the results is questionable, since the possibility that CTAP III is a contaminant of the platelet preparation was not excluded. First, attempts to express heparanase active CTAPIII/NAP2 protein were unsuccessful and the recombinant CTAPIII/NAP2 chemokines failed to exhibit heparanase activity. Second, western blot analysis of the platelet enzyme purified by Freeman and Parish (24) with antibodies against human β -thromboglobulin or platelet factor-4 demonstrated that these and related proteins (e.g., CTAP-III and NAP-2) were not present in the purified platelet heparanase preparations (24). Moreover, while heparanase activity can be detected in purified preparations of β -thromboglobulin, it is probably due to contamination with the "classical" platelet heparanase since it exhibited an endo-beta-D-glucuronidase activity rather than an endoglucosaminidase activity (23), as reported by Hoogewerf et al. (Pikas et al. manuscript submitted for publication).

Our studies on the immunolocalization of CTAPIII in human biopsy specimens revealed a preferential localization of CTAP-III in cells (i.e.,

vascular endothelia cells, keratinocytes) that failed to express heparanase activity and vice versa. Finally, none of the sequences published by Hoogewerf et al (platelet CTAP-III/NAP-2) (23) or Jin et al. (B16 melanoma) (26) nor sequences of the bacterial heparin/heparan sulfate degrading enzymes (hep I & III) (30a) were found in our recombinant human heparanase that was cloned and expressed on the basis of sequences derived from the purified human placenta and hepatoma heparanases.

Several years ago we prepared rabbit polyclonal antibodies directed against our partially purified preparation of human placenta heparanase. These antibodies, referred to in U.S. Pat. No. 5,362,641, were later found to be directed against plasminogen activator inhibitor type I (PAI-1) that was co-purified with the placental heparanase. These findings led to a modification of the original purification protocol to remove the PAI-1 contaminant.

Collectively, it is evident that so far no one had succeeded in eliciting anti-heparanase antibodies.

Unlike the above described information, both the polyclonal and monoclonal antibodies described hereinunder were raised, for the first time, against a purified, highly active, recombinant enzyme. As further shown below these antibodies specifically recognizes the heparanase enzyme in cell lysates and conditioned media and does not cross-react with β -thromboglobulin, NAP-2, PAI-1 or bacterial heparinases I and III. They do recognize the mouse B16-F10 heparanase, the human platelet heparanases, and the heparanase enzymes produced by several human tumor cell lines and Chinese hamster ovary (CHO) cells. By virtue of being produced against a purified recombinant enzyme and their specificity, these antibodies appear highly appropriate for diagnostic purposes such as immunohistochemistry of biopsy specimens and quantitative ELISA of body fluids (e.g., plasma, urine, pleural effusions, etc.). Similarly, as presented in the Examples section hereinunder, both the molecular probes for *in situ* determination of the tissue distribution of the *hpa* gene and the cDNA primers for detection of the *hpa* mRNA in normal and malignant cells of human origin (e.g., leukemia and lymphoma cells, melanoma cells) can be applied, for the first time, for diagnosis of early events in tumor progression, metastatic spread and response to treatment.

SUMMARY OF THE INVENTION

According to the present invention there are provided heparanase specific molecular probes and their use in use in research and medical applications including diagnosis and therapy.

5 According to further features in preferred embodiments of the invention described below, there is provided an antibody elicited by a heparanase protein or an immunogenical portion thereof, the antibody specifically binds heparanase.

10 According to still further features in the described preferred embodiments the heparanase protein is recombinant.

According to still further features in the described preferred embodiments the elicitation is through *in vivo* or *in vitro* techniques, the antibody having been prepared by a process comprising the steps of (a) exposing cells capable of producing antibodies to the heparanase protein or
15 the immunogenical part thereof and thereby generating antibody producing cells; (b) fusing the antibody producing cells with myeloma cells and thereby generating a plurality of hybridoma cells each producing monoclonal antibodies; and (c) screening the plurality of monoclonal antibodies to identify a monoclonal antibody which specifically binds
20 heparanase.

According to still further features in the described preferred embodiments the antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.

25 According to still further features in the described preferred embodiments the polyclonal antibody is selected from the group consisting of a crude polyclonal antibody and an affinity purified polyclonal antibody.

According to further features in preferred embodiments of the invention described below, there is provided an oligonucleotide comprising a nucleic acid sequence specifically hybridizable with heparanase encoding
30 nucleic acid.

According to further features in preferred embodiments of the invention described below, there is provided a pair of polymerase chain reaction primers comprising a sense primer and an antisense primers, each of the primers including a nucleic acid sequence specifically hybridizable
35 with heparanase encoding nucleic acid.

According to further features in preferred embodiments of the invention described below, there is provided an antisense nucleic acid

(RNA or DNA) molecule comprising a nucleic acid sequence specifically hybridizable with heparanase messenger RNA.

According to further features in preferred embodiments of the invention described below, there is provided a sense nucleic acid (RNA or DNA) molecule comprising a nucleic acid sequence specifically
5 hybridizable with heparanase antisense RNA.

According to further features in preferred embodiments of the invention described below, there is provided a method of *in situ* detecting localization and distribution of heparanase expression in a biological sample
10 comprising the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting the localization and distribution of the detectable heparanase specific molecular probe.

According to further features in preferred embodiments of the invention described below, there is provided a method of detecting
15 heparanase expression in a biological sample comprising the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting said detectable heparanase specific molecular probe. Protein and nucleic acid dot blot application are envisaged.

According to still further features in the described preferred
20 embodiments the biological sample is selected from the group consisting of cells and tissues.

According to still further features in the described preferred embodiments the biological sample is malignant.

According to still further features in the described preferred
25 embodiments the malignancy is selected from the group consisting of a solid tumor and a hematopoietic tumor.

According to still further features in the described preferred
embodiments the solid tumor is selected from the group consisting of carcinoma, adenocarcinoma, squamous cell carcinoma, teratocarcinoma,
30 mesothelioma and melanoma, and further wherein the hematopoietic tumor is selected from the group consisting of lymphoma and leukemia.

According to still further features in the described preferred
embodiments the solid tumor is a primary tumor, or a metastasis thereof, and is originated from an organ selected from the group consisting of liver,
35 prostate, bladder, breast, ovary, cervix, colon, skin, intestine, stomach, uterus, pancreas.

According to still further features in the described preferred
embodiments the detectable heparanase specific molecular probe is selected

from the group consisting of a nucleic acid sequence hybridizable with heparanase encoding nucleic acid and an anti-heparanase antibody capable of specifically binding heparanase.

According to still further features in the described preferred
5 embodiments the nucleic acid sequence hybridizable with heparanase encoding nucleic acid is selected from the group consisting of a synthetic oligonucleotide, an antisense heparanase RNA and heparanase DNA labeled by a detectable moiety.

According to further features in preferred embodiments of the
10 invention described below, there is provided a method of detecting heparanase protein in a body fluid of a patient comprising the steps of reacting the body fluid with an anti-heparanase antibody and monitoring the reaction.

According to still further features in the described preferred
15 embodiments the body fluid is selected from the group consisting of plasma, urine, pleural effusions and saliva.

According to still further features in the described preferred embodiments the body fluid is of a patient suffering from a condition selected from the group consisting of cancer, renal disease and diabetes.

20 According to still further features in the described preferred embodiments the renal disease is associated with diabetes.

According to still further features in the described preferred embodiments the anti-heparanase antibody is selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

25 According to still further features in the described preferred embodiments reacting the body fluid with the anti-heparanase antibody is effected in solution.

According to still further features in the described preferred
30 embodiments reacting the body fluid with the anti-heparanase antibody is effected on a substrate capable of adsorbing proteins present in the body fluid.

According to still further features in the described preferred
embodiments the body fluid is of a patient suffering from myeloma, breast carcinoma, metastatic breast carcinoma, hemorrhagic nephritis, nephrotic
35 syndrome, normoalbuminuric type I diabetes, microalbuminuric type I diabetes, kidney disorder, inflammation, sepsis, inflammatory and autoimmune disease.

According to further features in preferred embodiments of the invention described below, there is provided a method of detecting the presence, absence or level of heparanase transcripts in a biological sample comprising the steps of (a) extracting messenger RNA from the biological sample, thereby obtaining a plurality of messenger RNAs; (b) reverse transcribing the plurality of messenger RNAs into a plurality of complementary DNAs; (c) contacting the plurality of complementary DNAs with a pair of heparanase specific polymerase chain reaction primers, nucleoside triphosphates and a thermostable DNA polymerase; (d) performing a polymerase chain reaction; and (e) detecting the presence, absence or level of the polymerase chain reaction product.

According to further features in preferred embodiments of the invention described below, there is provided a method of detecting heparanase messenger RNA in a biological sample comprising the steps of reverse transcribing the messenger RNA into complementary DNA, contacting the complementary DNA with polymerase chain reaction oligonucleotides hybridizable to heparanase encoding nucleic acid, performing a polymerase chain reaction and monitoring for heparanase specific polymerase chain reaction products.

According to further features in preferred embodiments of the invention described below, there is provided a method of detecting the presence, absence or level of heparanase protein in a biological sample comprising the steps of (a) extracting proteins from the biological sample, thereby obtaining a plurality of proteins; (b) size separating the proteins; (c) interacting the size separated proteins with an anti-heparanase antibody; and (d) detecting the presence, absence or level of the interacted anti-heparanase antibody.

According to still further features in the described preferred embodiments the anti-heparanase antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.

According to still further features in the described preferred embodiments the size separation is effected by electrophoresis.

According to further features in preferred embodiments of the invention described below, there is provided a method of targeted drug delivery to a tissue of a patient, the tissue expressing heparanase, the method comprising the steps of providing a complex of a drug directly or indirectly linked to an anti-heparanase antibody and administering the complex to the patient.

According to further features in preferred embodiments of the invention described below, there is provided a method of treating a patient having a condition associated with heparanase expression comprising the step of administering an anti-heparanase antibody to the patient.

5 It is an object of the present invention to use a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression.

It is another object of the present invention to use a heparanase specific molecular probe for therapy of a condition associated with
10 expression of heparanase.

It is yet another object of the present invention to use a heparanase specific molecular probe for quantification of heparanase in a body fluid.

It is still another object of the present invention to use a heparanase specific molecular probe for targeted drug delivery.

15 It is another object of the present invention to use a heparanase specific molecular probe as a therapeutic agent.

The present invention successfully addresses the shortcomings of the presently known configurations by providing a variety of heparanase specific molecular probes which can be used for research and medical
20 applications including diagnosis and therapy.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention herein described, by way of example only, with reference to the accompanying drawings, wherein:

25 FIG. 1 demonstrates the expression of the human heparanase gene by human breast carcinoma cell lines with different metastatic potentials. Total RNA was isolated and subjected to semi quantitative RT-PCR (28 cycles) using human heparanase primers (hep) and primers for the GAPDH housekeeping gene. Reactions without reverse transcriptase demonstrated
30 no amplification of genomic DNA contamination in the RNA samples (not shown). Lane 1, Non metastatic MCF-7 cells, lane 2, moderate metastatic MDA-231 cells, lane 3, highly aggressive MDA-435 cells, lane 4, minimal metastatic ZR-75 cells, lane 5, moderate metastatic MCF-ANeoT cells, lane 6, highly metastatic MCF-T6 3B cells; lane 7, DNA molecular weight
35 marker VI (Boehringer Mannheim).

FIGs. 2a-b demonstrate heparanase activity expressed by human breast carcinoma cell lines with different metastatic potentials. Breast carcinoma cell lysates of the above described cell lines were incubated (24

hours, 37 °C, pH 6.2) with ³⁵S-HSPG isolated from intact subendothelial ECM. Heparanase mediated conversion of the heparan sulfate substrate (peak I) into low MW degradation fragments (peak II) was analyzed by gel filtration on Sepharose 6B. Expression of the human *hpa* gene correlates
5 with heparanase activity and metastasis in experimental animals.

FIGs. 3a-f demonstrate detection of *hpa* mRNA by in situ hybridization in specimens of normal and malignant human breast tissue with antisense heparanase RNA probe: invasive carcinoma of the breast, pre-malignant fibrocystic breast tissue, adenocarcinoma of the breast,
10 invasive breast carcinoma surrounding the area of tumor necrosis (not stained), normal breast tissue-reduction mammoplasty (antisense *hpa* probe), and normal breast tissue-reduction mammoplasty (control sense probe), respectively.

FIG. 4 demonstrate heparanase activity expressed by human prostate carcinoma cell lines. Expression of the human *hpa* gene by normal and malignant human prostate cells. Total RNA was isolated and subjected to RT-PCR using the appropriate human *hpa* primers (hep) and primers for the GAPDH housekeeping gene. Reactions without reverse transcriptase demonstrated no genomic DNA contamination in the RNA samples (not
20 shown). Lane 1, metastatic DU145 human prostate carcinoma cells, lane 2, metastatic PC3 human prostate carcinoma cells, lane 3, normal human prostate tissue (biopsy specimen), lane 4, DNA molecular weight marker VI (Boehringer Mannheim).

FIG. 5 demonstrate the expression of the *hpa* gene by high and low metastatic human bladder carcinoma and mouse T lymphoma cell lines. Total RNA was isolated and subjected to RT-PCR using human *hpa* primers. Lane 1, non metastatic MBT2 human bladder carcinoma cells,
25 lane 2, highly metastatic T50 variant of MBT2 cells, lane 3, non-metastatic Eb mouse T-lymphoma, lane 4, highly metastatic ESb variant of the Eb mouse T-lymphoma cells, lane 5, DNA molecular weight marker VI (Boehringer Mannheim). -RT: negative control, without reverse transcriptase, P: non amplified primers.

FIGs. 6a-c demonstrate heparanase activity expressed by high and low metastatic human bladder carcinoma cells. Media conditioned by low
35 (MBT2) and high (T50) metastatic human bladder carcinoma cells were incubated (24 hours, 37 °C, pH 6.2) with ³⁵S-HSPG isolated from intact subendothelial ECM. Heparanase mediated conversion of the heparan sulfate substrate (peak I, ss 47) into low molecular weight degradation

fragments (peak II) was analyzed by gel filtration on Sepharose 6B. Expression of the human *hpa* gene correlates with heparanase activity and metastasis in experimental animals.

FIG. 7 demonstrate expression of the *hpa* gene by high and low metastatic B16 mouse melanoma cell lines. Total RNA was isolated and subjected to RT-PCR using *hpa* primers (hep) and primers for the GAPDH housekeeping gene. Reactions without reverse transcriptase demonstrated no genomic DNA contamination in the RNA samples. Lane 1, highly metastatic B16-F10 mouse melanoma cells, lane 2, low metastatic B16-F1 mouse melanoma cells, lane 3, DNA molecular weight marker VI (Boehringer Mannheim).

FIG. 8a demonstrate expression of the *hpa* gene by biopsy specimens from malignant human melanoma tumors and non-malignant benign nevus tissue which were processed for cell culture. Total RNA was isolated from subconfluent cultures and subjected to RT-PCR using human specific *hpa* primers (hep). Representative cases are shown. Lane 1, malignant melanoma, lane 2, non-malignant nevus tissue, lane 3, *hpa*-pcDNA plasmid (positive control), lane 4, negative control (no RNA), lane 5, DNA molecular weight marker VI (Boehringer Mannheim). Reactions without reverse transcriptase (-RT) demonstrated no genomic DNA contamination in the RNA samples.

FIG. 8b demonstrates heparanase activity expressed by cultured cells derived from malignant melanoma (patient M-24) and non-malignant nevus tissue (patient M-31). Cultured cells were seeded on sulfate labeled ECM. Labeled degradation fragments released into the incubation medium were subjected to gel filtration on sepharose 6B.

FIGs. 9a-f demonstrate detection of *hpa* mRNA by *in situ* hybridization in specimens of human malignant melanoma and normal nevus. Figures 9a, c and d - metastatic human melanoma (3 different patients), Figure 9b - non malignant nevus tissue. Labeling is not seen in the nevus tissue, as compared to intense staining of the metastatic melanoma. Figures 9e and f - same sections as in Figures c and d stained with hematoxylin-eosine.

FIGs. 10a-f demonstrate detection of *hpa* mRNA by *in situ* hybridization in specimens of normal and malignant human liver. Hepatocellular carcinoma (x 200), hepatocellular carcinoma (x 1000), liver adenocarcinoma, normal adult liver, embryonic liver and control sense staining of embryonic liver are shown respectively. Labeling is not seen in

normal liver cells as compared to intense staining of embryonic and malignant liver cells.

FIGs 11a-f demonstrate detection of *hpa* mRNA by *in situ* hybridization in specimens of normal and malignant human tissues.

5 Adenocarcinoma of the ovary, normal ovary, squamous cell carcinoma of the cervix, normal cervix, colon adenocarcinoma and normal small intestine are shown respectively.

FIGs 12a-f demonstrate detection of *hpa* mRNA by *in situ* hybridization in specimens of various human tumors. Positive staining of
10 the *hpa* gene was clearly seen in adenocarcinoma of the stomach, teratocarcinoma, well differentiated endometrial adenocarcinoma, adenocarcinoma of the pancreas, mesothelioma, Figures 12a-e, respectively. Control, sense staining of human mesothelioma is shown in Figure 12f.

FIGs. 13a-b demonstrate expression of heparanase in human
15 leukemias and lymphomas. Peripheral white blood cells of patients with various types of leukemia and lymphoma were isolated and tested for expression of the human *hpa* gene. For this purpose, total RNA was isolated and subjected to RT-PCR using human specific *hpa* primers. Reactions without reverse transcriptase demonstrated no genomic DNA
20 contamination in the RNA samples. Peripheral white blood cells of different patients with chronic lymphocytic leukemia (Figure 13a, lanes 1-5) were isolated and tested for expression of the human *hpa* gene. 13a Lane 6, *hpa*-pcDNA plasmid (positive control), lane 7, negative control (no reverse transcriptase), lane 8, DNA molecular weight marker VI (Boehringer Mannheim). Representative patients with various types of leukemia and
25 lymphoma are shown in Figure 13b. Lane 1, acute myelocytic leukemia, lane 2, Chronic lymphocytic leukemia (atypical B cell), lane 3, acute myelocytic leukemia (M5), lane 4, hairy cell leukemia, lane 5, non-hodjkin lymphoma (mature B cells), lane 6, non-hodjkin lymphoma (mature B
30 cells), lane 7, chronic lymphocytic leukemia (stage I), lane 8, acute myelocytic leukemia (M2), lane 9, chronic myelocytic leukemia, lane 10, chronic lymphocytic leukemia (stage II), lane 11, acute lymphocytic leukemia, lane 12, chronic lymphocytic leukemia (stage III), lane 13, acute myelocytic leukemia (M1), lane 14, acute myelocytic leukemia (M3), lane
35 15, *hpa*-pcDNA plasmid (positive control), lane 16, negative control (no reverse transcriptase), lane 17, DNA molecular weight marker VI (Boehringer Mannheim).

FIG. 14 demonstrates no expression of the *hpa* gene by normal human umbilical cord white blood cells. Total RNA was isolated and subjected to RT-PCR using *hpa* primers (hep) and primers for the GAPDH housekeeping gene. Reactions without reverse transcriptase demonstrated no genomic DNA contamination in the RNA samples. Lanes 1-6, white blood cell preparations from 6 different umbilical cords, lane 7, *hpa*-pcDNA plasmid (positive control), lane 8, negative control (no reverse transcriptase), lane 9, DNA molecular weight marker VI (Boehringer Mannheim).

FIG. 15 demonstrates expression of the *hpa* gene by leukemia and lymphoma cell lines. Total RNA was isolated and subjected to RT-PCR using *hpa* primers (hep) and primers for the GAPDH housekeeping gene. Reactions without reverse transcriptase demonstrated no genomic DNA contamination in the RNA samples. Lane 1, normal B lymphoblastoid cell line (Monga), lane 2, Burkitt B lymphoma (Raji), lane 3, Burkitt B lymphoblasts (Daudi), lane 4, Burkitt B lymphoblasts (non Ebv, DG-75), lane 5, erythroleukemia (K-562), lane 6, pre B lymphoma (nalm6), M = DNA molecular weight marker VI (Boehringer Mannheim).

FIGs. 16a-h demonstrate urinary heparanase activity. Urine samples (o) of healthy donor (16d) and patients with multiple myeloma (16a), bilateral breast carcinoma (16b), metastatic breast carcinoma (16c), hemorrhagic nephritis (16e) nephrotic syndrome (16f), normoalbuminuric (16g) and microalbuminuric type I diabetes (16h) were incubated (24 hours, 37 °C, pH 6.2) with ³⁵S-HSPG (50 µl) isolated from intact subendothelial ECM (♦). Heparanase mediated conversion of the heparan sulfate substrate (peak I) into low molecular weight degradation fragments (peak II) was analyzed by gel filtration on Sepharose 6B.

FIGs. 17a-b demonstrate Western blots of extracts of cells expressing various segments of heparanase as detected with polyclonal anti heparanase antibodies. 17a - antiserum from rabbit 7640, 17b - antiserum from rabbit 7644. Lane 1, *E. coli* BL21(DE3)pLysS cells transfected with pRSET, lane 2, *E. coli* BL21(DE3)pLysS cells transfected with pRSET containing the heparanase entire open reading frame (543 amino acids, SE ID NOs: 2 and 3), lane 3, *E. coli* BL21(DE3)pLysS cells transfected with pRSET*hpa*BK containing 414 amino acids of the heparanase open reading frame (amino acids 130-543 of SEQ ID NOs: 2 and 3), lane 4, *E. coli* BL21(DE3)pLysS cells transfected with pRSET*hpa*BH containing 302 amino acids of the heparanase open reading frame (amino acids 130-431 of SEQ ID NOs: 2

and 3), lane 5, molecular size markers, lane 6, medium of Sf21 insect cells infected with recombinant Baculovirus pFhpa containing the heparanase entire open reading frame (543 amino acids, SEQ ID NOs: 2 and 3), lane 7, Sf21 insect cells infected with recombinant baculovirus with no insert.

5 Proteins were separated on 10 % SDS-PAGE, antisera were diluted 1:1,000. Detection was performed by ECL (Amersham) according to the manufacturer's instructions. Size in kDa is shown to the right, as was determined using prestained SDS-PAGE standards, Bio-Rad, CA..

FIG. 18 demonstrates Western blot using affinity purified polyclonal
10 antibodies with heparanase expressed in various expression systems. Lane 1, medium of Sf21 insect cells infected with recombinant Baculovirus pFhpa, lane 2, cell extract of a Chinese hamster ovary (CHO) clone stably transfected with a vector containing no insert, lane 3, cell extract of a CHO stable clone transfected with hpa cDNA, lane 4, proteins precipitated from
15 medium of the yeast *Pichia pastoris* transfected with hpa cDNA. Proteins were separated on 4-20 % gradient SDS-PAGE, antibody was diluted 1:100. Detection was performed by ECL (Amersham) according to the manufacturer's instructions. For CHO and *Pichia* clones see U.S. Pat. application No. 09/260,038, which is incorporated by reference as if fully set forth herein. Size in kDa is shown to the right, as was determined using
20 prestained SDS-PAGE standards, Bio-Rad, CA..

FIGs. 19a-b demonstrate Western blot of extracts of various cell types using anti-heparanase polyclonal antibodies. 19a - crude antiserum diluted 1:2,000, 19b - affinity purified antibodies diluted 1:100. lane 1,
25 purified heparanase from placenta, lanes 2 and 3, cell extracts of platelets, insoluble and soluble fractions, respectively, lanes 4 and 5, cell extracts of neutrophils, insoluble and soluble fractions, respectively, lanes 6 and 7, cell extracts of mouse melanoma B16-F1 cells, insoluble and soluble fractions, respectively. Proteins were separated on 8-16 % gradient gel. Detection
30 was performed by ECL (Amersham) according to the manufacturer's instructions. Size in kDa is shown to the right, as was determined using prestained SDS-PAGE standards, Bio-Rad, CA..

FIG. 20 demonstrates Western blot of recombinant and native heparanases from various origins using supernatant of hybridoma HP-117.
35 Lanes 1 and 2, 293 human kidney cells non-transfected and transfected with hpa-pCDNA, respectively (15 µg), lane 3, CHO cells stably transfected with pShpa (40 µg), lane 4, mock transfected CHO cells (40 µg), lane 5, purified recombinant heparanase produced by baculovirus

infected insect cells (50 ng), lane 6, cell extracts of *E. coli* expressing recombinant heparanase (50 ng), lane 7, cell extract of human platelets (100 µg), lane 8, prestained SDS-PAGE standard, Bio-Rad, CA. Proteins were separated on 4-20% gradient SDS-PAGE and transferred to a nylon membrane (Amersham). Membrane was incubated with supernatant of hybridoma Hp117 and detection was performed with alkaline phosphatase conjugated anti-mouse IgG antibodies.

FIGs. 21a-b demonstrate immunostaining of heparanase in CHO cells with polyclonal antibodies. CHO cells transfected with the full length *hpa* gene (21a) were tested for overexpression of heparanase. Staining is detected in the cytoplasm of transfected cells. In non transfected CHO cells (21b), no staining of heparanase is detected.

FIGs. 22a-b demonstrate immunostaining of heparanase in CHO cells with monoclonal antibody HP-130. CHO cells transfected with the full length *hpa* gene (22a) were tested for overexpression of heparanase. Staining is detected in the cytoplasm of transfected cells. In non transfected CHO cells (22b), no staining of heparanase is detected.

FIGs. 23a-c demonstrate immunostaining of heparanase in blood smears from normal donor with monoclonal antibody HP-92. Heparanase is found in the cytoplasm of neutrophils (23a) and platelets (23c) but is not detected in lymphocytes (23b) and monocytes (23c).

FIG. 24 demonstrates a typical standard curve of recombinant human heparanase. Standard curve was constructed by plotting the log of the heparanase concentration at the x-axis versus the log of the absorbance at the y-axis.

FIG. 25 demonstrates epitope mapping of monoclonal antibodies HP-117 and HP-239. The different polypeptides, as indicated below, were fractionated on SDS-PAGE and transferred to a nitrocellulose membrane (Schleicher and Schull). The membrane was reacted with either antibody HP-117 or HP-239 as indicated above. Lane 1 - cell extracts containing heparanase segment of 414 amino acids of the heparanase open reading frame (amino acids 130-543). Lane 2 - cell extracts containing a heparanase segment of 314 amino acids of the heparanase open reading frame (amino acids 230-543). Lane 3 - cell extracts containing heparanase segment of 176 amino acids of the heparanase open reading frame (amino acids 368-543). Lane 4 - cell extracts containing heparanase segment of 79 amino acids of the heparanase open reading frame (amino acids 465-543). Lane 5 - cell extracts containing heparanase segment of 229 amino acids of

the heparanase open reading frame (amino acids 1-229). Lane 6 - cell extracts containing heparanase segment of 347 amino acids of the heparanase open reading frame (amino acids 1-347). Lane 7 - cell extracts containing heparanase segment of 465 amino acids of the heparanase open reading frame (amino acids 1-465). Lane 8, size markers (Bio-Rad).

FIG. 26a-d demonstrate preferential immunohistochemical staining of heparanase in a colonic polyp, and in primary and metastatic human colon adenocarcinoma. Paraffin embedded tissue specimens derived from: (a) colon epithelium removed from a normal region located away from the neoplastic lesion; (b) tubulovillous adenoma; (c) primary human colon adenocarcinoma; and (d) colon carcinoma metastasized to the liver, were subjected to immunostaining with monoclonal anti-heparanase antibody HP-92.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is of heparanase specific molecular probes which can be used in research and medical applications. Specifically, the present invention can be used for the detection and monitoring of malignancies, metastasis and other, non-malignant conditions, efficiency of therapeutic treatments, targeted drug delivery and therapy, using heparanase specific molecular probes, such as anti-heparanase antibodies (both poly- and monoclonal) and heparanase gene (*hpa*) derived nucleic acids, including, but not limited to, PCR primers, antisense oligonucleotide probes, antisense RNA probes, DNA probes and the like.

The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.

As shown in the Examples section below heparanase specific antibodies and/or nucleic acids reveals *in situ* expression (protein and/or messenger RNA) of heparanase in a variety of cells and tissues, especially

in malignant cells and tissues, wherein the degree of expression corroborates with metastasis.

Therefore, according to one aspect of the present invention there is provided a method of *in situ* detecting localization and distribution of heparanase expression in a biological sample. The method comprises the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting the localization and distribution of the detectable heparanase specific molecular probe.

According to another aspect of the present invention, there is provided a method of detecting heparanase expression in a biological sample. The method comprises the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting the detectable heparanase specific molecular probe. Protein and nucleic acid dot blot application are envisaged.

As used herein in the specification and in the claims section below, the term "heparanase expression" refers mainly to the processes of transcription and translation, resulting in a catalytically active heparanase having endoglycosidase hydrolyzing activity which is specific for heparin or heparan sulfate proteoglycan substrates, as opposed to the activity of bacterial enzymes (heparinase I, II and III) which degrade heparin or heparan sulfate by means of β -elimination.

As used herein in the specification and in the claims section below, the term "biological sample" refers to cells and tissues, including, but not limited to cancer cells and tissues. The term further relates to body fluids, as further detailed below.

As used herein in the specification and in the claims section below, the term "detectable heparanase specific molecular probe" and its equivalent term "detectable heparanase molecular probe" both refer to a nucleic acid sequences hybridizable with heparanase encoding nucleic acid or to an anti-heparanase antibody capable of specifically binding heparanase. The nucleic acid sequence hybridizable with heparanase encoding nucleic acid is, for example, a synthetic oligonucleotide, an antisense heparanase RNA or heparanase DNA, and it is preferably labeled by the detectable moiety.

As used herein in the specification and in the claims section below, the term "detectable moiety" refers to any atom, molecule or a portion thereof, the presence, absence or level of which is directly or indirectly monitorable. One example include radioactive isotopes. Other examples include (i) enzymes which can catalyze color or light emitting

(luminescence) reactions and (ii) fluorophores. The detection of the detectable moiety can be direct provided that the detectable moiety is itself detectable, such as, for example, in the case of fluorophores. Alternatively, the detection of the detectable moiety can be indirect. In the latter case, a second moiety reactable with the detectable moiety, itself being directly detectable is preferably employed. The detectable moiety may be inherent to the molecular probe. For example, the constant region of an antibody can serve as an indirect detectable moiety to which a second antibody having a direct detectable moiety can specifically bind.

As used herein in the specification and in the claims section below, the term "antibody" refers to any monoclonal or polyclonal immunoglobulin, or a fragment of an immunoglobulin such as sFv (single chain antigen binding protein), Fab1 or Fab2. The immunoglobulin could also be a "humanized" antibody, in which murine variable regions are fused to human constant regions, or in which murine complementarity-determining regions are grafted onto a human antibody structure (Wilder, R.B. et al., J. Clin. Oncol., 14:1383-1400, 1996). Unlike mouse or rabbit antibodies, "humanized" antibodies often do not undergo an undesirable reaction with the immune system of the subject. The terms "sFv" and "single chain antigen binding protein" refer to a type of a fragment of an immunoglobulin, an example of which is sFv CC49 (Larson, S.M. et al., Cancer, 80:2458-68, 1997).

According to one embodiment of the invention the biological sample is malignant, e.g., it is a solid tumor or hematopoietic tumor sample. The solid tumor can, for example, be of the types: carcinoma, adenocarcinoma, squamous cell carcinoma, teratocarcinoma, mesothelioma or melanoma, which are shown hereinunder in the Examples section to express heparanase in good correlation to the degree of metastasis. The hematopoietic tumor can, for example, be lymphoma or leukemia.

In some embodiments of the present invention the solid tumor is a primary tumor, or a metastasis thereof, and it originates from an organ such as, for example, liver, prostate, bladder, breast, ovary, cervix, colon, skin, intestine, stomach, uterus (including embryo) and pancreas.

As shown in the Examples section below, it was further found that body fluids (e.g., urine) of patients with certain conditions include catalitically active heparanase. These conditions include myeloma, breast carcinoma, metastatic breast carcinoma, hemorrhagic nephritis, nephrotic syndrome, normoalbuminuric type I diabetes, microalbuminuric type I

diabetes, kidney disorder, inflammation, sepsis, inflammatory and autoimmune disease.

Therefore, according to another aspect of the present invention there is provided a method of detecting heparanase protein in a body fluid of a patient. The method comprises the steps of reacting the body fluid with an anti-heparanase antibody, either poly or monoclonal antibody, and monitoring the reaction. The body fluid is, for example, plasma, urine, pleural effusions or saliva. Monitoring the reaction may be effected by having the antibody labeled with a detectable moiety, or to use its constant region as an inherent detectable moiety, to which a second antibody which includes a detectable moiety can specifically bind.

Urine heparanase was detected in patients suffering from conditions such as cancer, renal disease and diabetes. In some cases the renal disease was associated with diabetes.

According to a preferred embodiment of the present invention reacting the body fluid with the anti-heparanase antibody is effected in solution. Alternatively, reacting the body fluid with the anti-heparanase antibody is effected on a substrate capable of adsorbing proteins present in the body fluid, all as well known in the art of antibody based diagnosis.

As further shown in the Examples section below, RT-PCR proves useful in detecting the presence, absence or level of heparanase transcripts in various biological samples.

Therefore, according to another aspect of the present invention there is provided a method of detecting the presence, absence or level of heparanase transcripts in a biological sample. The method comprises the following steps. First, messenger RNA (e.g., as a component of total RNA) is extracted from the biological sample, thereby a plurality of messenger RNAs are obtained. Second, the plurality of messenger RNAs are reverse transcribed into a plurality of complementary DNAs. Third, the plurality of complementary DNAs are contacted with a pair of heparanase specific polymerase chain reaction (PCR) primers, nucleoside triphosphates and a thermostable DNA polymerase (e.g., *Thermophilus aquaticus* DNA polymerase, native or recombinant) and a polymerase chain reaction is performed by temperature cycling, as well known in the art. Finally, the presence, absence or level of the polymerase chain reaction product is detected, e.g., by gel electrophoresis, by monitoring the incorporation of a detectable moiety into the product or any other applicable way, all as well known in the art.

As further shown in the Examples section below, protein blots and anti-heparanase antibodies prove useful in detecting the presence, absence or level of heparanase protein in various biological samples.

Therefore, further according to the present invention there is provided a method of detecting the presence, absence or level of heparanase protein in a biological sample. The method comprises the following steps. First, proteins are extracted from the biological sample, thereby a plurality of proteins are obtained. The protein extract may be a crude extract and can also include non-proteinacious material. Second, the proteins are size separated, e.g., by electrophoresis, gel filtration etc. Fourth, the size separated proteins are interacted with an anti-heparanase antibody, either poly or monoclonal antibody. Finally, the presence, absence or level of the interacted anti-heparanase antibody is detected. In case of gel electrophoresis the interaction with the antibody is typically performed following blotting of the size separated proteins onto a solid support (membrane).

In many cases it was shown that directly or indirectly (e.g., via liposomes) linking a drug (e.g., anti cancerous drug, such as, for example radio isotopes) to an antibody which recognized a protein specifically expressed by a tissue sensitive to the drug and administering the antibody-drug complex to a patient, results in targeted delivery of the drug to the expressing tissue.

Therefore, according to yet another aspect of the present invention there is provided a method of targeted drug delivery to a tissue of a patient, the tissue expressing heparanase. The method comprises the steps of providing a complex of a drug directly or indirectly linked to an anti-heparanase antibody and administering the complex to the patient. External radio imaging is also envisaged, wherein the drug is replaced with an imageable radio isotope. Endoscopic or laparoscopic imaging is also envisaged. In the latter cases the drug is typically replaced by a fluorescence or luminescence substance. These procedures may, for example, be effective in finding/destroying micrometastases.

In other cases, it was shown that administering an antibody capable of binding epitopes associated with certain tissues provide means of destroying such tissues by an elicited immune response.

Therefore, according to another aspect of the present invention there is provided a method of treating a patient having a condition associated with

heparanase expression. The method comprises the step of administering an anti-heparanase antibody to the patient.

Further according to the present invention there is provided an antibody elicited by a heparanase protein (e.g., recombinant) or an immunogenical portion thereof, the antibody specifically binds heparanase. The antibody can be a poly or monoclonal antibody. If it is poly clonal and produced *in vivo*, it is preferably affinity purified, however crude antibody preparations are also applicable, all as shown and described in more detail in the Examples section hereinunder.

Preferably, the elicitation of the antibody is through *in vivo* or *in vitro* techniques, the antibody having been prepared by a process comprising the steps of, first, exposing cells capable of producing antibodies to the heparanase protein or the immunogenical part thereof and thereby generating antibody producing cells. second, fusing the antibody producing cells with myeloma cells and thereby generating a plurality of hybridoma cells each producing monoclonal antibodies, and third, screening the plurality of monoclonal antibodies to identify a monoclonal antibody which specifically binds heparanase.

Further according to the present invention there is provided an oligonucleotide comprising a nucleic acid sequence specifically hybridizable with heparanase encoding nucleic acid, be it heparanase DNA or RNA. The oligonucleotide may include natural nucleotides and/or nucleotide analogs, such as, but not limited to phosphorothioated analogs. Such oligonucleotides are readily synthesized provided that the sequence is known. Such oligonucleotides can be deduced, for example, from SEQ ID NOs: 1 and 3.

Further according to the present invention there are provided an antisense nucleic acid (RNA or DNA) molecule comprising a nucleic acid sequence specifically hybridizable with heparanase messenger RNA and a sense nucleic acid (RNA or DNA) molecule comprising a nucleic acid sequence specifically hybridizable with heparanase antisense RNA.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.

EXPERIMENTAL METHODS AND MATERIALS

Cells: Cultures of bovine corneal endothelial cells (BCECs) were established from steer eyes as previously described (19, 31). Stock cultures were maintained in DMEM (1 gram glucose/liter) supplemented with 10 % newborn calf serum, 5 % fetal calf serum (FCS). bFGF (1 ng/ml) was added every other day during the phase of active cell growth (14, 15). Hybridoma cells were cultured in T-175 flasks (Corning Costar, Cat. No. 430824) inside a CO₂-enriched incubator (8 %), at 37 °C. DMEM medium (Beit Haemek, Israel) was added with 10 % horse serum (Beit-Haemek Cat. No. 04-124-1A). Culture volume was 80 ml.

Preparation of sulfate labeled substrates: BCECs (second to fifth passage) were plated into 35 mm tissue culture plates at an initial density of 2×10^5 cells/ml and cultured in DMEM supplemented with 10 % FCS and 5 % dextran T-40 for 12 days. Na₂³⁵SO₄ (25 µCi/ml) was added on day 1 and 5 after seeding and the cultures were incubated with the label without medium change. The subendothelial ECM was exposed by dissolving (5 min, room temperature) the cell layer with PBS containing 0.5 % Triton X-100 and 20 mM NH₄OH, followed by four washes with PBS. The ECM remained intact, free of cellular debris and firmly attached to the entire area of the tissue culture dish (14, 15, 20).

To prepare soluble sulfate labeled proteoglycans (peak I material), the ECM was digested with trypsin (25 µg/ ml, 6 hours, 37 °C), the digest was concentrated by reverse dialysis, applied onto a Sepharose 6B gel filtration column and the high molecular weight material (K_{av} < 0.2, peak I) was collected (32). More than 80 % of the labeled material was shown to be composed of heparan sulfate proteoglycans (11).

Heparanase activity: Cells (1×10^6 /35-mm dish), cell lysates or conditioned medium were incubated on top of ³⁵S-labeled ECM (18 hours, 37 °C) in the presence of 20 mM phosphate or phosphate citrate buffer (pH 6.2). Cell lysates and conditioned media were also incubated with sulfate labeled peak I material (10-20 µl). The incubation medium was collected, centrifuged (18,000 g, 4 °C, 3 min), and sulfate labeled material was analyzed by gel filtration on a Sepharose CL-6B column (0.9 x 30 cm). Fractions (0.2 ml) were eluted with PBS at a flow rate of 5 ml/hour and counted for radioactivity using Bio-fluor scintillation fluid. The excluded volume (V₀) was marked by blue dextran and the total included volume (V_t) by phenol red. The latter was shown to comigrate with free sulfate (11,

20). Degradation fragments of HS side chains were eluted from Sepharose 6B at $0.5 < K_{av} < 0.8$ (peak II) (11, 20). A nearly intact HSPG released from ECM by trypsin was eluted next to V_0 ($K_{av} < 0.2$, peak I). Recoveries of labeled material applied on the columns ranged from 85 to 95 % in different experiments.

Construction of heparanase expression vector: A *Bam*HI-*Kpn*I 1.3 kb fragment (nucleotides 450-1721 of the *hpa* sequence, SEQ ID NOs: 1 and 3, U.S. Pat. application No. 08/922,170) was cut out from *pfasthpa* and cloned into pRSET-C bacterial expression vector (Invitrogen). The resulting recombinant plasmid pRSET*hpa*BK encodes a fusion protein comprised of His tag, a linker sequence and amino acids 130-543 of the heparanase protein (SEQ ID NOs: 2 and 3).

A 1.6 kb fragment of *hpa* cDNA was amplified from *pfasthpa* (a *hpa* cDNA cloned in *pfastBac*, see U.S. patent No. 08/922,170), by PCR using specific sense primer: (Hpu-550*Nde*) - 5'- CGCATATGCAGGACGTCGTG GACCTG-3' (SEQ ID NO:4) and a vector specific antisense primer: (3'*pFast*) 5'-TATGATCCTCTAGTACTTCTCGAC-3' (SEQ ID NO:5). The upper primer introduced an *Nde*I site and an ATG codon preceding nucleotide 168 of *hpa*. The PCR product was digested by *Nde*I and *Bam*HI and its sequence was confirmed. pRSET*hpa*BK was digested with *Nde*I and *Bam*HI and ligated with the *Nde*I-*Bam*HI *hpa* fragment. The resulting plasmid, designated pRSET*hpa*S1, encoded an open reading frame of 508 amino acids (36-543) of the heparanase protein, lacking the N-terminal 35 amino acids which are predicted to be a signal peptide. Expression constructs were introduced into *E. coli* BL21(DEL3)pLysS cells (Stratagene), according to supplier's protocol.

Preparation of antigen: *E. coli* cells harboring the recombinant plasmid were grown at 37 °C overnight in Luria broth containing ampicillin and chloramphenicol. Cells were diluted 1/10 in the same medium, and the cultures were grown to an OD600 of approximately 0.5. Isopropyl-thiogalactoside (IPTG) (Promega) was added to a final concentration of 1 mM and the culture was incubated at 37 °C for 3 hours. Cells from induced cultures were cooled on ice, sedimented by centrifugation at 4,000 x g for 20 minutes at 4 °C, and resuspended in 0.5 ml of cold phosphate-buffered saline (PBS). Cells were lysed by sonication, and cell debris was sedimented by centrifugation at 10,000 x g for 20 minutes. The resulting pellet was analyzed by 10 % SDS-PAGE. The gel was stained with 1 x PBS coomassie blue and the band of 45 kDa which contained the

recombinant heparanase was cut out and crashed through a needle (21G) attached to a syringe. For immunization of mice, the crashed gel was incubated in PBS overnight at 4 °C and the protein diffused into the buffer was collected. Rabbits were injected with gel homogenate.

5 The 55 kDa protein (508 amino acids) was purified from *E. coli* inclusion bodies by preparative SDS-PAGE, using a Model 491 Prep Cell (Bio-Rad) which is designed to purify proteins from complex mixtures by continuous elution electrophoresis. This antigen was used for ELISA screening.

10 **Immunization - polyclonal antibodies:** Two rabbits (designated 7640 and 7644) were immunized each with 200 µg of protein emulsified with equal volume of complete Freund's adjuvant. An equal amount of protein emulsified with incomplete Freund's was injected to each rabbit two weeks following the first injection and again after another four weeks. Ten
15 days after the third injection the rabbits were bled and serum was examined for reactivity with recombinant heparanase. Four weeks after bleeding another boost was injected and 10 days later blood was collected.

Immunization - monoclonal antibodies: 6 to 8 weeks old female Balb/C mice were each immunized intradermally with 50 µg recombinant
20 heparanase emulsified in 50 µl PBS complete Freund's adjuvant. Two to three weeks later the same amount of the emulsion was injected subcutaneously or intradermally at multiple sites in incomplete Freund's adjuvant. After 3 weeks 25 µg antigen in aqueous solution was injected intraperitoneally. 7-10 days later animals were bled and the titer of the
25 relevant antibodies was determined. 3-4 weeks after the last boost, one or two animals were injected intraperitoneal with 20 µg of soluble antigen (in PBS) and 3-4 days later spleens were removed.

Fusion and cloning: The spleens of immunized mice were ground, splenocytes were harvested and fused with the NSO myeloma cells by
30 adding 41 % PEG. Hybridoma cells were grown in HAT-selective DMEM growth media containing 15 % (v/v) HS (Beit Haemek), 2 mM glutamine, Pen-Strep-Nystatin solution (Penicillin: 10,000 units/ml, Streptomycin: 10 mg/ml, Nystatin: 1,250 units/ml), at 37 °C in 8 % CO₂ containing atmosphere. Hybridoma cells were cloned by limiting dilution.
35 Hybridomas producing Mabs to human heparanase were identified by reactivity with solid-phase immobilized human heparanase.

ELISA: Falcon polyvinyl plates were coated with 50 ng/well of baculovirus derived human heparanase (native) and 100 ng/well of *E. coli*

derived human heparanase (55 kDa - non-active) in PBS (pH 7.2) overnight at 40 °C. Hybridoma tissue culture supernatants were added to the wells, and incubated at room temperature for 2 hours. Binding of Mabs was then detected by incubation with HRP-conjugated goat anti mouse IgG (Fab specific) (Sigma), followed by development in o-phenylenediamine substrate (Sigma) and measurement of absorbencies at 450 nm. PBS with 0.05 % Tween was used to wash the plates between incubations. Polyclonal rabbit anti human heparanase was used as positive control and negative control included coating with PBS or irrelevant supernatant.

Affinity purification of polyclonal antibodies: 200 µg of recombinant heparanase were separated on 10 % SDS-PAGE. Following electrophoresis protein was transferred to a nitrocellulose membrane (Schleicher & Scuell). Membrane was stained with Ponceau S and the heparanase band was cut out. The membrane strip was blocked for 2 hours in TBS containing 0.02 % Tween 20 and 5 % skim milk. Antiserum was diluted 1:3 in blocking solution and incubated with the membrane for 16 hours. Membrane strip was washed with 0.15 M NaCl for 20 minutes and then with PBS for additional 20 minutes. Antibodies were eluted with 0.2 M glycine, 1 mM EDTA pH 2.8 for 20 minutes at room temperature, and then neutralized by addition of 0.1 volumes of 1 M Tris pH 8.0 and 0.1 volumes of 10 x PBS. NaNO₃ was added to a final concentration of 0.02 %.

Western blot: Proteins were separated on 4-20 %, or 8-16 % polyacrylamide ready gradient gels (Novex). Following electrophoresis proteins were transferred to Hybond-P nylon membrane (Amersham) (350 mA/100V for 90 minutes). Membranes were blocked in TBS containing 0.02 % Tween 20 and 5 % skim milk for 1-16 hours, and then incubated with antisera diluted in blocking solution. Blots were then washed in TBS-Tween, incubated with appropriate HRP-conjugated anti mouse/anti rabbit IgG, and developed using ECL reagents (Amersham) according to the manufacturer's instructions. Alternatively, an alkaline phosphatase conjugated anti-mouse/anti-rabbit IgG antibodies were used as secondary antibodies and blots were developed with FAST™ BCIP/NBT (Sigma) according to the supplier's instructions.

Expression of the heparanase gene in various cell types and tissues (RT-PCR): RT-PCR was applied to evaluate the expression of the *hpa* gene by various cell types. For this purpose, total RNA was reverse transcribed and amplified, using the following cDNA primers: Human *hpa* - Hpu-355

5'-TTCGATCCCAAGAAGGAATCAAC-3' (SEQ ID NO:6) and Hpl-229 -
5'-GTAGTGATGCCATGTAAGTGAATC-3' (SEQ ID NO:7).

Expression pattern of the heparanase gene transcript (in situ hybridization). *In situ* hybridization enables determination of the
5 distribution of *hpa* transcripts in normal and malignant tissues. For this
purpose, thin sections of biopsy specimens were processed for *in situ*
hybridization and hybridized with an antisense RNA probe to the *hpa* gene.
The experiments have the resolution power to unambiguously identify the
expressing cell type, be they tumor cells, tissue macrophages, mast cells or
10 platelets. Sections were treated with proteinase K to expose the target RNA
and to block non specific binding sites before addition of the probe (34).
For *in situ* hybridization, two digoxigenin labeled probes were prepared,
one in the sense direction and the other in the anti-sense direction. They
were both transcribed from a fragment of about 624 bp of the *hpa* cDNA
15 sequence (nucleotides 728-1351, SEQ ID NOs: 1 and 3) cloned in to the
EcoRI-HindIII sites of the transcription vector pT3T7-Pac (a modified
vector derived from pT3T7, Pharmacia), using T3 (for antisense) or T7 (for
sense) RNA polymerase, according to the suppliers protocol. Slides were
hybridized under appropriate conditions with the labeled probe and the
20 hybridized probe is visualized using colorimetric reagents (NBT & BCIP)
(34). Reactions were stopped when the desired intensity has been reached.

***In situ* detection of heparanase by antibodies:** *hpa*-transfected and
non transfected CHO cells were plated on 8-chamber tissue culture slides
(Nunc). Cells were fixed in 95% ethanol, 5% acetic acid for 5 minutes at -
25 20 °C. Cells were permeabilized using permeabilization buffer (20 mM
HEPES, pH 7.4; 300 mM Sucrose; 50 mM NaCl; 3 mM MgCl₂; 0.5 %
Triton X-100) for 4 minutes at 4 °C. Endogenous peroxidases were blocked
using 0.3 % H₂O₂ in methanol and non specific binding sites were blocked
using 5 % horse serum in PBS. Monoclonal anti-heparanase antibody
30 (supernatant of hybridoma) was applied and incubated with the cells
overnight at room temperature. Antibody was washed away and
biotinylated secondary antibody (horse-anti mouse, Vector, Vectastain ABC
system) was added for 30 minutes at room temperature. Immunostaining
was detected using Di Amino Benzidine and H₂O₂ (Sigma tablets) until
35 desired staining-intensity was achieved. Slides were counterstained with
Mayer's hematoxylin. Immunostaining with polyclonal antibodies was
performed under the same conditions, affinity purified antibody was used at
1:500 dilution. Biotinylated horse anti-rabbit was used as a secondary

antibody (Vector, Vectastain ABC system). Blood smears were prepared from a healthy donor. Fixation and staining were performed as described above.

Production of antibodies by the starvation method (39): Cultures reaching cell density of 2×10^6 cells/ml or higher were used for the production of antibodies. Cells were removed from flasks by pipetting and were centrifuged at 1,000 rpm for 5 minutes in order to pellet the cells. The cell pellets were suspended in basal DMEM (with no serum added) and centrifuged at 1,000 rpm for 5 minutes. This procedure was repeated once more and the cell pellets resulted were suspended in the original volume of basal DMEM medium as before centrifugation. Cell suspension was plated into new T-175 flasks and placed inside the incubator. After 48 hours, cells were pelleted by centrifugation at 3,500 rpm for 10 minutes. Culture supernatants were filtered through 0.2 micron pore-size filter (Nalgene, Cat. No. 156-4020) and added with sodium azide at 0.05 % final concentration. Culture supernatants were kept refrigerated until purification.

Adaptation of hybridomas to serum-free medium:

Hybridoma cells were seeded at 3×10^5 cells/ml in duplicates in cluster well plate in serum-free medium. Serum was added to the wells to a final concentration of 5 %, 2.5 %, 1.25 %, 0.63 %, 0.31 % and 0 %. Every three days in culture, cells viability was determined in the wells. Wells which had more than 80 % viable cells out of the total cell population (as determined by Trypan Blue staining) were used for continuing the process of adaptation. These cells were shifted to serum free medium that contained half the percentage of serum as before. After three more days the process of evaluating viability score of the cells and feeding with fresh media was repeated to the point of complete elimination of serum from cells. Cells were considered adapted if they had more than 80 % of cell population viable after at least three days in culture without serum. This procedure was adapted from "Monoclonal antibodies" by J.H. Perets et al. Springer Publisher.

Purification of monoclonal antibodies: Purification was preformed by affinity chromatography using Protein G (39, 40). 2.5 ml of Protein G Sepharose 4 (Fast Flow) (Pharmacia Cat. No. 17-0618-01) were used to pack each column (Bio Rad, Cat. No. 737-1517). The flow rate for packing the columns was 4 ml/min. Column was equilibrated with 100 ml of PBS pH 7.2. Culture supernatants (filtered and supplemented with sodium azide as described above) were loaded on the column at a flow rate of 1

ml/minute. After loading, column was washed with 80 ml of PBS pH 7.2 at a flow rate of 4 ml/minute. Elution was with 12 ml of 0.1 M Glycine-HCl buffer pH 2.7 at a flow rate of 1 ml/minute. One ml fractions were collected into tubes containing 0.3 ml of 1 M Tris pH 9.0. Column was further washed after elution with 50 ml of the elution buffer at a flow rate of 4 ml/min. Column was then regenerated by passing 50 ml of regeneration buffer (0.1 M Glycine-HCl buffer pH 2.5). After regeneration, the column was immediately neutralized with 100 ml of PBS pH 7.2. 0.1% sodium azide was added and the column stored in the refrigerator.

Eluted fractions were analyzed for protein content using the Bradford protein determination method. According to the results obtained, 4-6 fractions were pooled and dialyzed (Spectrum dialysis tubing, MWCO 6,000-8,000, Cat. No. 132653) three times against 500 ml of PBS buffer pH 7.2 with 0.05 % sodium azide, or against PBS pH 7.2 with 1 % thimerosal (Sigma, Cat. No. T-8784) added. After dialysis samples were stored at 4°C.

Labeling of HP239 with biotin: Antibody containing PBS solution at 1.9 mg/ml was dialyzed against 0.1 M NaCO₃ (Sigma Cat. No. S-5761), pH 8.3-8.5, twice, for 4 hours each time, at 4 °C. Dialysis tubing was from Spectrum (Spectra/Por, MWCO 6,000-8,000). Labeling the antibody with biotin was by adding Biotin amido caproate N-hydroxysuccinimide ester (Sigma Cat. No. B-2643) dissolved in DMSO (Merck Cat. No. 2950) to the antibody solution. 80 µl of the Biotin amido caproate N-hydroxysuccinimide ester solution were added to 1 ml of the antibody solution. The mixture was vortexed immediately, covered with aluminum foil to prevent light exposure and placed at room temperature for 4 hours for labeling to take place. After completion of the labeling period, the antibody solution was dialyzed twice against PBS added with sodium azide to 0.05 % and stored in the refrigerator.

HABA test: HABA test was performed on biotinylated antibody in order to determine the molar ratio between the biotin and antibody molecules. The result of this test is the B/P ratio which indicate the extent of labeling of the antibody. To this end, 1 mg of Avidin (Sigma Cat. No. A-9275) was dissolved in 50 mM phosphate buffer with 0.15 M NaCl pH 6.0. 2.42 mg of 2-(4'-Hydroxyazobenzene) benzoic acid (HABA) (Pierce, Cat. No. 28010) were dissolved in 1 ml of 10 mM NaOH solution. 0.5 mg of d-Biotin were dissolved in 1 ml of 50 mM phosphate buffer with 0.15 M NaCl pH 6.0. Biotin solution was diluted from 0.5 mg/ml to 0.05 mg/ml in 50

mM phosphate buffer with 0.15 M NaCl pH 6.0. Standard curve for d-Biotin was performed by adding 25 μ l of HABA solution to 0.5 ml of Avidin solution and transferred to quartz glass cuvettes. OD was determined at 500 nm, then 5 μ l of the conjugated antibody were added to the cuvette and OD was determined again at 500 nm. This process was repeated until OD500 decreased up to the value obtained with 1 μ g biotin per sample on the standard curve. Conjugate curve was plotted as well as the standard curve and bound biotin was calculated.

Epitope mapping: A 1.7 Kb fragment of *hpa* cDNA (a *hpa* cDNA cloned in pfastBacHTA, see U.S. Pat. application No. 08/922,170, which is incorporated herein by reference) was digested by various restriction enzymes to create serial deletions from both 3' and 5' ends of the heparanase open reading frame (ORF) as follows:

(i) 3' deletions: *EcoRI-BstEII* fragment, encoding amino acids 1-465, deletion of an *NdeI-XbaI* fragment generating an ORF of 347 amino acids (1-347) and a deletion of *AflII-XbaI* fragment generating an ORF of 229 amino acids (1-229).

(ii) 5' deletions: *BamHI-XhoI* fragment encoding 414 amino acids (130-543), an *AflII-XhoI* fragment encoding 314 amino acids (230-543), an *NdeI-XhoI* fragment encoding 176 amino acids (368-543) and a *BstEII-XhoI* fragment encoding 79 amino acids of the heparanase open reading frame (465-543).

The heparanase segments were expressed in a Baculovirus expression system essentially as described in U.S. Pat. No. 09/260,038. The fragments were subcloned into the vector pfastBacHT to generate His tagged fusion constructs. Recombinant baculovirus containing the various fragments were generated using the Bac to Bac system (GibcoBRL) according to the manufacturer recommendations. Extracts of Sf21 cells expressing various segments of heparanase protein were analyzed. The recombinant heparanase segments were detected by Western blots.

Subtype analysis: Subtype analysis of hybridoma cell culture supernatants was performed by using Sigma immunotype mouse monoclonal antibody isotyping kit and the Boehringer Mannheim Isostrip mouse monoclonal antibody isotyping kit according to the manufacturer's instructions.

Principle of sandwich ELISA: Precise recognition of heparanase is made with two monoclonal antibodies (HP-117 and HP-239) which were obtained after immunization of mice with heparanase protein. Heparanase

p60 ELISA is based on the double-antibody sandwich method. Two monoclonal antibodies were prepared against sterically remote sites on the heparanase molecule, the first (HP-117) being coated on the ELISA solid phase; the second, biotinylated (HP-239) is used as a detectable antibody (tracer). Heparanase molecules present in the standards or the samples to be tested are "sandwiched" between the two antibodies. Excess unbound of tracer is easily removed during the washing step, and the ELISA retains only the absorbed antibody/antigen/tracer combination. The amount of color generated is directly proportional to the amount of heparanase present in standard or samples. The recombinant heparanase used as standard was produced in baculovirus and purified as described in U.S. Pat. application 09/260,038.

The heparanase p60 ELISA contains microtiter wells, precoated in coating solution (carbonate/bicarbonate buffer 0.05 M pH 9.6) with monoclonal antibody (HP-117) to heparanase and blocked with blocking solution (PBS-1 %, BSA-0.05 % and Tween-20) to prevent non-specific binding. A measured volume of sample or heparanase standard diluted in sample diluent (PBS-1%, BSA-0.05% and Tween-20-0.1%SDS) were added to each test well and incubated to allow any heparanase present to be bound by antibodies on the microtiter plate. The wells were washed with wash solution (PBS-0.05 %, Tween-20) and a biotinylated antibody to heparanase was added, which binds to the captured heparanase during incubation. After washing, a peroxidase-conjugated neutravidin reagent was added, which attached to the biotin in the immune complex on plate during incubation. Following incubation, the wells were washed and substrate solution (tetramethylbenzidine-TMB) was added to the wells, producing a blue color in the presence of peroxidase. The color reaction was stopped by the addition of acid (2 M sulfuric acid), which changes the blue color to yellow. The intensity of the yellow color is proportional to the amount of heparanase present in the samples or standards. The absorbance of each well was measured at 450 nm in reference to 630 nm. A standard curve was generated by plotting the log of absorbency versus the log of concentration of the heparanase standard (Figure 24). The heparanase concentration of the unknown specimen was determined by comparing the optical density of the specimen to the standard curve. The standard used in this assay is recombinant human heparanase calibrated against BSA by SDS polyacrylamide gel.

EXPERIMENTAL RESULTS

Differential expression of the hpa gene in human breast carcinoma and breast carcinoma cell lines:

Semi-quantitative RT-PCR was applied to evaluate the expression of the *hpa* gene by human breast carcinoma cell lines exhibiting different degrees of metastasis (35, 36). While the non-metastatic MCF-7 breast carcinoma line failed to express the expected 585 bp cDNA of the *hpa* gene (Figure 1, lane 1), moderate (MDA 231, Figure 1, lane 2) and highly (MDA 435, lane 3) metastatic breast carcinoma cell lines exhibited a marked increase in *hpa* gene expression. The differential expression of the *hpa* gene was reflected by a similar differential pattern of heparanase activity. As demonstrated in Figure 2a, lysates of MCF-7 cells exhibited little or no heparanase activity, as compared to a moderate and high activity expressed by MDA-231 and MDA-435 cells, characterized by moderate and high metastatic potential in nude mice, respectively.

The same pattern of *hpa* gene expression and heparan sulfate degrading activity was observed in another model of breast cancer. While the ZR75 (=MCF10A) dysplastic breast cell line originated from fibrocystic breast epithelial cells showed little or no expression of the *hpa* gene (Figure 1, lane 4), Ha-ras transfected ZR75 cell line (MCF10AT and MCF10AT3B) expressed the *hpa* gene (lanes 5 and 6) in correlation with their metastatic potential. The highly metastatic MCF10AT3B cells were derived from the third generation of xenografted tumors (36). The heparanase activity expressed by these cell lines was in correlation with their metastatic behavior (Figure 2b).

In subsequent experiments, sense and antisense deoxigenin labeled RNA probes (600 bp fragment of the *hpa* cDNA) were employed to screen archival paraffin embedded human breast tissue for expression of the *hpa* gene transcripts by *in situ* hybridization.

As shown in Figures 3a-f, massive expression of the *hpa* gene was observed in invasive breast carcinoma (3a) and breast adenocarcinoma (3c). The *hpa* gene was already expressed by differentiated epithelial cells of pre-malignant fibrocystic breast (3b) and in breast carcinoma tissue surrounding the area of tumor necrosis where little or no staining was observed (3d). Unlike the malignant tissue, normal breast tissue failed to express the *hpa* transcript as revealed by the lack of staining in tissue derived from reduction mammoplasty, both by the antisense (3e) and sense (3f) *hpa* probes.

Altogether, these results demonstrate a preferential expression of the *hpa* gene malignant breast carcinoma cells, indicating a potential application in early diagnosis of the disease, particularly in view of the positive staining detected already in the fibrocystic stage.

5 **Human prostate and bladder carcinomas:** Differential expression of the *hpa* mRNA was also suggested by RT-PCR analysis of several human prostate and bladder carcinoma cell lines. As demonstrated in Figure 4, both DU145 (lane 1) and PC3 (lane 2) human prostate cell lines showed high expression of the *hpa* mRNA in contrast to lack of, or non-
10 detectable, expression in a biopsy of normal adult prostate tissue (lane 3). Similarly, as demonstrated in Figure 5, highly metastatic variant (T50) of the non-metastatic MBT2 human bladder carcinoma cell line, exhibited a much higher expression of the *hpa* gene (lane 2) as compared with the MBT2 cell line (lane 1). This difference was also reflected by high
15 heparanase activity secreted into the culture medium of the aggressive T50 cells, as compared to no detectable activity in the medium of the parental MBT2 cells (Figures 6a-c). Again, the observed differential expression of the *hpa* gene and enzyme activity points toward potential application in the diagnosis of metastatic human prostate and bladder carcinomas.

20 **Mouse melanoma and T-lymphoma:** Differential expression of the *hpa* mRNA and heparan sulfate degrading activity, correlated with the metastatic potential in mice was also demonstrated in studies with mouse B16 melanoma and T-lymphoma. In fact, the melanoma (9, 37) and lymphoma (11) cell systems were the first experimental systems pointing
25 toward an important role of heparanase in tumor cell invasion and metastasis. Our cloning of the *hpa* cDNA, encoding for the heparanase enzyme, provides, for the first time, an evidence that the difference in enzymatic activity is due primarily to a preferential expression of the *hpa* gene by highly metastatic tumor cells. Thus, as demonstrated in Figures 5 and 7, the highly metastatic ESb lymphoma (Figure 5, lane 4) and B16-F10
30 melanoma (Figure 7, lane 1) cell lines, expressed the *hpa* gene to a much higher extent as compared to the parental low metastatic Eb lymphoma (Figure 5, lane 3) and B16-F1 melanoma (Figure 7, lane 2) cells. The respective high and low levels of heparanase activity by these cell lines
35 were reported in earlier studies (9, 11, 37).

Human melanoma: Preferential expression of the *hpa* gene and enzyme activity was also observed in cells derived from biopsies of human melanoma and normal nevus tissue. Biopsy specimens of malignant

melanoma are routinely processed for cell culture in the department of Oncology (Hadassah Hospital, Jerusalem) for immunotherapy purposes. Cultured cells derived from 16 out of 16 patients (see also Table 1, below) expressed the *hpa* gene, as revealed by RT-PCR (Figure 8a, lane 1, a representative patient). Melanoma cells derived from 3 of these patients were tested for degradation of soluble heparan sulfate proteoglycans and were found to be highly active (Figure 8b). In contrast, cells derived from a non-malignant nevus tissue showed no detectable expression of the *hpa* mRNA (Figure 8a, lane 2) and no enzyme activity (Figure 8b).

Similar results were obtained using archival paraffin embedded biopsy specimens and *in situ* hybridization. Again, cytoplasmic labeling of the *hpa* mRNA was observed in tissue sections of metastatic specimens derived from 3 different patients with malignant melanoma (Figures 9a and 9c-d), but not from a non-malignant nevus (Figure 9b). Altogether, these results imply a potential use of *hpa* specific primers, nucleic acid probes and antibodies in early diagnosis of melanoma metastasis.

Human liver carcinoma: The heparanase enzyme was first purified in our laboratory from a human hepatoma cell line (Sk-Hep-1). In fact, amino acid sequences derived from the purified hepatoma heparanase were used to clone the *hpa* gene. *In situ* hybridization studies revealed an intense expression of the *hpa* gene in tissue sections derived from human hepatocellular carcinoma (Figures 10a-b) and liver adenocarcinoma (Figure 10c). The *hpa* mRNA was not expressed by adult normal liver tissue (Figure 10d). It was expressed, however, in embryonic human liver (Figure 10e). Each of these examples clearly supports the use of heparanase specific molecular probes as tools for early diagnosis of human cancer and its spread and response to anti-cancer treatments.

Other human tumors: A preferential expression of the *hpa* gene was clearly observed by *in situ* hybridization performed with biopsy specimens of several different human carcinomas in comparison with their normal tissue counterparts. As demonstrated in Figures 11a-f, an intense expression of the *hpa* gene was observed in tissue sections derived from adenocarcinoma of the ovary (Figure 11a), squamous cell carcinoma of the cervix (Figure 11c), and colon adenocarcinoma (Figure 11e). In contrast, there was little or no expression of the *hpa* mRNA in human tissue sections derived from normal ovary (Figure 11b), cervix (Figure 11d) and small intestine (Figure 11f). The few cells stained in the normal tissue specimens were single infiltrating macrophages and neutrophils.

Positive staining of the *hpa* gene was also clearly seen in adenocarcinoma of the stomach (Figure 12a), teratocarcinoma (Figure 12b), well differentiated endometrial adenocarcinoma (Figure 12c), adenocarcinoma of the pancreas (Figure 12d), and mesothelioma (Figure 12e). Each of these examples clearly supports the use of heparanase specific molecular probes as tools for early diagnosis of human cancer and its spread and response to anti-cancer treatments.

Human leukemia and lymphoma: We have previously applied time consuming measurements of heparanase activity and demonstrated that heparanase is expressed and readily secreted by acute and chronic human myeloid leukemic cells (AML and CML), but not by chronic lymphocytic leukemic cells (CLL). The availability of heparanase specific primers enables a more sensitive and rapid determination of *hpa* gene expression by human leukemia and lymphoma cells. For this purpose, peripheral white blood cells (derived from patients with leukemia and lymphoma) were purified on Ficoll-hypack and subjected to total RNA isolation and RT-PCR determination of the *hpa* mRNA. Altogether, cells of 69 patients were tested. Representative patients are presented in Figures 13a-b and the results are summarized in Table 1 below. Cells from 31 out of 31 patients with CLL showed no detectable expression of the *hpa* gene (Figure 13a, lanes 1-5, Figure 13b, lanes 2, 7, 10 and 12) regardless of the stage of the disease. Similar results were obtained with cells from 4 out of 4 patients with non-Hodgkin lymphoma (NHL) (Figure 13b, lanes 5 and 6). Both the CLL and NHL cells represent primarily differentiated B cells. In contrast, the *hpa* mRNA was expressed by cells derived from 14 out of 14 patients with AML (Figure 13b, lane 11). These cells represent undifferentiated myeloblasts of neutrophils and monocyte origin. The *hpa* mRNA was expressed in cells of 1 out of 3 patients with CML, and 2 out of 2 patients with acute lymphocytic leukemia. Surprisingly, umbilical cord blood derived white blood cells showed little (one case) or no expression (13 additional cases) of the *hpa* gene in different cord blood samples (Figure 14, Table 1, below). These cord blood preparations are enriched with hematopoietic stem cells. Studies with established cell lines (Figure 15) revealed no expression of the *hpa* mRNA in Burkitt B lymphoma (i.e., Raji, Daudi, DG-75, lanes 2-4, respectively), as opposed to mature normal B (Ebv transformed) lymphoblastoid cell line (i.e., monga, Figure 15, lane 1) and erythroleukemia (K-562, lane 5).

Apparently, heparanase expression can distinguish between differentiated B cell lymphoma (CLL and NHL) and undifferentiated myelocytic and lymphoblastoid leukemia (AML and ALL) (Table 1). The lack of *hpa* gene expression by umbilical cord white blood cells may enable to distinguish between early normal white blood cells (*hpa* negative) and early leukemic cells (*hpa* positive). Furthermore, the presence of heparanase may distinguish between early lymphatic leukemic cells (*hpa* positive) and late B leukemia and lymphoma cells (*hpa* negative).

Table 1
Expression of hpa mRNA (RT-PCR) in human leukemia, lymphoma and melanoma

Type	# of patients	# <i>hpa</i> positive	# <i>hpa</i> negative
CLL	31	0	31
AML	14	14	0
ALL	2	2	0
CML	3	1	2
NHL	4	0	4
Cord blood	14	1	13
Melanoma	16	16	0
Nevus (normal)	3	0	3

Heparanase activity in the urine of cancer patients: In an attempt to elucidate the involvement of heparanase in tumor progression and its relevance to human cancer, we screened urine samples for heparanase activity. Heparanase activity was determined by incubation of urine with soluble sulfate labeled proteoglycans obtained by trypsin digestion of metabolically $\text{Na}_2^{35}\text{SO}_4$ labeled subendothelial extracellular matrix. Heparanase activity resulted in conversion of a high molecular weight (MW) sulfate labeled substrate into low MW heparan sulfate degradation fragments as determined by gel filtration analysis. Heparanase activity was detected in the urine of 21 (renal cell carcinoma, breast carcinoma, rhabdomyosarcoma, stomach cancer, myeloma) out of 157 cancer patients. Three examples are given in Figures 16a-c. High levels of heparanase activity were determined in the urine of patients with an aggressive disease (primarily breast carcinoma, Figures 16b-c, multiple myeloma, Figure 16a)

and there was no detectable activity in the urine of healthy donors (Figure 16d). A more sensitive ELISA is expected to detect the heparanase protein at early stages of the disease. Urine may also contain heparanase inhibitors (i.e., GAGs) and hence an activity assay may under estimate the number of patients with positive urinary heparanase protein.

Heparanase activity in the urine of diabetic patients: Reduction in glomerular basement membrane (GBM) heparan sulfate proteoglycan (HSPG) is responsible for the microalbuminuria and proteinuria of diabetic nephropathy. We identified heparanase activity in cultured rat mesangial cells and postulated that the reduction in glomerular HSPG is secondary to increased glomerular heparanase activity and that the latter will be manifested by an increase in urinary heparanase. Urinary heparanase activity was tested in samples from 70 patients with type I diabetes and in 40 sex and age matched controls, as described above. The results are summarized in Table 2 below. Fifty patients were normoalbuminuric (NA) while 20 had microalbuminuria (MA). Urinary heparanase activity was detected in 13 of 70 (19 %) diabetic patients while it was absent in the control group ($p=0.002$). Sixteen percent of the NA patients and 25 % of the MA patients showed urinary heparanase activity (Figures 16g-h). Interestingly, over 80 % of the heparanase positive patients were females. Heparanase positive patients had significantly higher blood glucose ($p=0.0005$) and HbA1C ($p=0.03$) levels compared with heparanase negative diabetic patients. This is the first study suggesting a role for heparanase in the pathogenesis of diabetic nephropathy. Urinary heparanase may be an early marker for renal involvement in type I diabetic patients, anteceding MA. The presence of heparanase activity in the urine of normo and microalbuminuric IDDM (insulin dependent diabetic mellitus) patients, is most likely due to diabetic nephropathy, the most important single disorder leading to renal failure in adults.

Table 2

Heparanase activity in urine of IDDM patients

	No. of patients	Averaged Age	Sex	Disease duration	Blood pressure	GFR	Heparanase positive
Normo-albuminuria	50	26.2 ± 8.5 years	26 males 24 females	16.5 ± 7.3 years	112 ± 17	134 ± 25 ml/min/1.73 m ²	8/50 (16 %)
Microalbuminuria	20	26.5 ± 11. years	10 males 10 females	14.5 ± 7.9 years	115 ± 13	128 ± 26 ml/min/1.73 m ²	5/20 (25 %)

5 Repeated determination of urinary heparanase in 9 IDDM patients yielded similar results (6 negative and 3 positive) to the initial analysis performed 3 months earlier. Our results suggest that heparanase activity may play a role in the regulation of the number of HSPG anionic sites in the GBM and hence may modulate the permselective properties of the
10 glomerular basement membrane.

Heparan sulfate contributes to the assembly and integrity of the ECM through binding to various ECM molecules such as collagen, laminin, fibronectin, thrombospondin and tenascin. Cleavage of heparan sulfate may therefore result in disassembly of the ECM leading to a loss of its barrier
15 properties. We have identified heparanase activity expressed by mesangial cells (not shown). Once heparanase is secreted by stimulated mesangial cells it will degrade heparan sulfate in the GBM thus allowing its passage into the urinary space.

Heparanase activity was also detected in the urine of proteinuric
20 patients not suffering from diabetes (Figures 16e-f). These included patients with focal segmental glomerulosclerosis, minimal change nephrotic syndrome and congenital nephrotic syndrome, thus indicating that the involvement of heparanase in the generation of proteinuria may not be limited to diabetic nephropathy. Urinary heparanase activity seems to be
25 detected more frequently as the degree of proteinuria increases. Active heparanase was detected in the urine of 15 % of normoalbuminuric and 25 % microalbuminuric type I diabetic patients. The prevalence reached 48 % in a group of 28 macroalbuminuric patients with NIDDM.

Diabetic nephropathy, occurring in approximately 30 % of patients
30 with type I diabetes, is a major cause of end stage renal disease. The inability to discriminate the subpopulation that will develop renal damage

prior to the appearance of microalbuminuria, 10-15 years following the diagnosis of diabetes, prevents us from significantly changing the devastating natural history of the disease. Urinary heparanase activity is a distinguishing feature, occurring in 30-35 % of normoalbuminuric females, within an otherwise homogenous group of patients.

This is the first result suggesting a role for heparanase in the pathogenesis of proteinuria in type I diabetes. Obviously, measurements of urinary heparanase activity is both time consuming and not sensitive enough. Moreover, we have demonstrated the presence of an inhibitor of mammalian heparanase in the urine of normal individuals. The nature of this inhibitory substance, possibly urinary glycosaminoglycans is currently being studied. Urinary heparanase activity is therefore the result of a balance between the presence in the urine of the enzyme and its inhibitor(s). Immunodetection of the heparanase protein is therefore a more sensitive and straightforward approach for diagnostic purposes. Altogether, our results clearly indicate that anti-heparanase antibodies that identify the heparanase antigen can be applied for early diagnosis of cancer metastasis and renal diseases. As discussed above, it is conceivable that heparanase may overcome the filtration barrier of the glomerular basement membrane and ECM simply by virtue of its ability to degrade the HS moieties that are held responsible for their permeaselective properties. Urinary heparanase is therefore expected to reflect the presence of heparanase in the circulation and hence be a sensitive marker for metastatic, inflammatory and kidney disease. Of particular significance is the potential ability to follow the course of tumor progression and spread, response to anti-cancer treatments, and possible relapse of the disease in a given patient. Targeted drug delivery and therapy are another aspect of the use for such antibodies.

Anti-heparanase polyclonal antibodies: Antisera from two immunized rabbits were examined by western blot for reactivity with various segments of recombinant heparanase expressed in *E. coli* and with the Baculovirus expressed heparanase (Figures 17a-b). In both cases, the polyclonal antibody recognized proteins of the expected size in *E. coli* derived recombinant heparanase, about 60 kDa for the entire open reading frame (lanes 2), about 45 kDa for the 414 amino acids *Bam*HI-*Kpn*I *hpa* fragment (lanes 3) and 35 kDa for the 302 amino acids encoded by a *Bam*HI-*Hind*III *hpa* fragment (lanes 4). A protein of approximately 65 kDa was recognized in the medium of Sf21 insect cells infected with recombinant Baculovirus pF*hpa* (lanes 7).

The specificity of affinity purified polyclonal antibodies was determined by Western blot with recombinant heparanase expressed in various expression systems, baculovirus infected insect cells, the yeast *Pichia pastoris* and CHO cells transfected with the *hpa* cDNA. For details about the CHO and *Pichia* clones see U.S. Pat. application No. 09/260,038, which is incorporated by reference as if fully set forth herein.

The specificity of the purified antibody is demonstrated in Figure 18. The purified antibody identified a single about 65 kDa protein expressed by *Pichia pastoris* (Figure 18, lane 4), and a major band of similar size expressed by Sf21 cells infected with recombinant baculovirus (Figure 18, lane 1). In a CHO stable transfected clone, 65 kDa and 50 kDa bands are detected (Figure 18, lane 3) as compared with the negative control (Figure 18, lane 2). In several experiments the two forms of the recombinant heparanase were identified, the higher form appeared as 60 to 65 kDa and the lower form as 45 to 50 kDa. Antibody 7644 was more specific and detected mainly the bands of the recombinant heparanase. 7460 detected several other cross reactive bands.

As shown in Figures 19a, crude polyclonal antibodies recognized multiple bands in human platelets (lanes 2 and 3) and neutrophils cell extracts (lanes 4 and 5), as well as mouse melanoma cell line B16 (lanes 6 and 7). However, as shown in Figure 19b, affinity purified antibodies recognized the 65 kDa and 50 kDa forms of heparanase purified from placenta (lane 1), two major bands in platelets extract, an upper band of approximately 50 kDa which corresponds with the lower band of the purified protein and a lower band of about 30 kDa (lanes 2 and 3). The 50 kDa protein appears in mouse melanoma cells as well as two bands of a higher molecular weight and several minor bands, which represent cross reactive proteins or other species of heparanase (lanes 6 and 7).

Monoclonal antibodies: Eight hundreds hybridomas, generated following 3 fusions were screened by ELISA for reactivity against human heparanase (native and denatured). Eight positive hybridomas were selected. Table 3 below summarizes the characteristics of the 8 hybridomas.

Table 3

Relative reactivity of hybridomas supernatants with native and denatured recombinant human heparanase

Hybridoma	ELISA		Western blotting
	Native	Denature	
HP-6	-	+	n.d.
HP-40	+++	++	n.d.
HP-45	+	++	n.d.
HP-92	++	+++	n.d/
HP-117	++++	+++	60,45,42 kDa
HP-130	++++	+++	n.d.
HP-239	++++	+++	n.d.
HP-303	-	++	n.d.

5 n.d. - not determined

Immunoblot of native and recombinant heparanase expressed in various cell types was performed using the supernatant of hybridoma HP-117 (Figure 20). A major band of approximately 50 kDa was detected in
 10 extract of stably transfected CHO cells (lane 3) and in platelets extract (lane 6). This band is also detected in transfected 293 cells as compared to the negative control (lanes 2 and 1 respectively). A band of approximately 42 kDa was observed in all mammalian cell extracts, including the negative control. This band probably represent a cross reactive protein or an
 15 endogenous form of heparanase. The 65 kDa recombinant heparanase purified from medium of baculovirus infected insect cells is clearly observed in lane 5 as well as a band of 53 kDa in lane 6 which is the expected size of the 508 amino acids heparanase polypeptide expressed in the *E. coli* cells

20 Both polyclonal and monoclonal antibodies were used successfully for detection of heparanase in intact cells by immunohistochemistry. Polyclonal antibodies showed specific staining of CHO cells transfected with pShpaCdhfr expression vector as described in patent U.S. Pat. application No. 09/260,038, which is incorporated by reference as if fully
 25 set forth herein, as compared with no staining of the non-transfected CHO cells (Figures 21a-b). Similar results were obtained with several monoclonal antibodies. Figures 22a-b demonstrate the specific staining of

heparanase in the cytoplasm of transfected CHO cells, with supernatant of hybridoma HP-130. No staining was observed in non-transfected cells. Monoclonal antibody HP-92 showed a specific staining of neutrophils and platelets in blood smear of a healthy donor (Figures 23a-c). This expression pattern is consistent with the high levels of heparanase activity characteristic of these cells.

Availability of anti-heparanase antibodies will enable development of immunological assays for screening tissue and body fluids for heparanase. An ELISA will provide a more sensitive and convenient means of detection as compared to the currently available assays of heparanase activity which do not appear sensitive enough for the detection of the enzyme in non-concentrated plasma and body fluids.

ELISA will provide a powerful diagnostic tool for quantitative determination of heparanase concentrations in serum, plasma, urine and other biological fluids. Although platelets and activated cells of the immune system (11) can express heparanase activity under certain conditions, we have detected little or no heparanase activity in normal human plasma. The possibility arises that with cancer patients, particularly those with leukemia and lymphoma, heparanase is secreted into the blood stream. In fact, our studies indicate that both acute and chronic human myeloid leukemic cells (AML and CML), but not chronic lymphocytic leukemic cells (CLL), secrete substantial amounts of heparanase during short incubation in PBS at 4 °C.

As described above, elevated levels of heparanase were detected in sera from metastatic tumor bearing animals and melanoma patients (13) and in tumor biopsies of cancer patients (15). High levels of heparanase activity were measured in the urine of patients with aggressive metastatic disease and there was no detectable activity in the urine of healthy donors.

Quantifying heparanase levels using monoclonal (Mab) antibodies:

Five hybridomas were isolated. Table 4 below summarizes the characteristics of the various antibodies produced and secreted thereby and as further detailed hereinunder.

Epitope Mapping: For some purposes it is necessary to determine whether individual monoclonal antibodies raised against the same antigen bind to identical or overlapping epitopes. A linear method was used to map the epitope recognized by each antibody within the heparanase protein. Serial deletion mutations were made and assayed for the production of fragments that can be recognized by an antibody. In practice, this method

can only localize the binding site to a small region. Supernatants from two monoclonal antibodies, HP-117 and HP-239 were examined by Western blot for reactivity with various segments of recombinant heparanase expressed in Baculovirus infected insect cells. As can be seen in Figure 25, monoclonal antibody HP-117 recognized a segment of 79 amino acids at the C-terminus of the heparanase open reading frame (amino acids 465-543). The monoclonal antibody HP-239 recognized an internal epitope localized to amino acids 130-160.

Table 4
characteristics of 4 Mab

Mab	W	IH	IP	EL	Neut	Epitope (aa)	Subclass
117	+			+	+	465-543	IgG1
239	+			+		130-160	IgG2a
130	+	+	+	+	++	465-543	IgG1
92		++		+		160-230	IgM

Heparanase p60 Sandwich ELISA: Urine p60 heparanase levels were measured in 21 normal people and in 10 patients with nephrologic disease by using the quantitative sandwich ELISA p60 heparanase. Urine samples were diluted 1:5 and 1:10 with sample diluent. The mean range for the normal people was 0 ng/ml, as compared to 11-160 ng/ml for the nephrologic patients. These preliminary clinical results of renal failure are showing that p60 heparanase assay can serve as a useful tool in the diagnosis of these patients.

Preferential expression of heparanase in human tumors: Preferential expression of heparanase in human tumors as compared with the corresponding normal tissues was demonstrated by immunohistochemical staining of paraffin embedded biopsy specimens. As demonstrated in Figures 26a-d, tissue sections from biopsy specimens of patients suffering from colon cancer (villous epithelial cells adenoma - 26a-b; colon adenocarcinoma - 26c-d) were stained with a monoclonal anti-heparanase antibody. Staining was noted primarily in villous epithelial cells

(26b-c) and to a lesser degree in connective tissue cells (26b-c). There was little or no staining of the normal colon epithelium located away from the neoplastic lesion in the villous epithelial cells adenoma patient (Figure 26a). Of particular significance was an intense immunostaining of colon carcinoma cells that had metastasized into the liver, as compared to the surrounding normal liver tissue (Figure 26d). Overexpression of heparanase may thus be a characteristic property of metastatic tumor cells.

The results presented above using the sandwich ELISA diagnostic technique may help improve the treatment of cancer by more accurately detecting the disease status and how patients are responding to therapy. For example, Biomira Diagnostics' TRUQUANT BR radioimmunoassay for the CA 27.29 antigen was shown in a clinical trial to predict the progression or remission of stage IV breast cancer. Researchers reported at the American Society of Clinical Oncology (ASCO) national meeting that 50 % increase or decrease in levels of the marker are significant indicators of progression or regression of the disease. Furthermore, CA 27.29 values changed as much as 105 days before changes in the patient's condition could be observed (38).

Levels of serum antigens can predict, whether chemotherapy or radiation are working. Answering that question definitively may be difficult if physicians rely solely on clinical symptoms or radioimaging to determine if tumors are progressing or regressing. In some cases, however, the detection of tumor associated antigens can serve as an early sign that therapy is ineffective and that the disease is worsening, that treatment may need to be changed, or that treatment is effective.

Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

LIST OF REFERENCES

1. Wight, T.N., Kinsella, M.G., and Qwarnstromn, E.E. (1992). The role of proteoglycans in cell adhesion, migration and proliferation. *Curr. Opin. Cell Biol.* 4: 793-801.
2. Jackson, R.L., Busch, S.J., and Cardin, A.L. (1991). Glycosaminoglycans: Molecular properties, protein interactions and role in physiological processes. *Physiol. Rev.* 71: 481-539.
3. Wight, T.N. (1989). Cell biology of arterial proteoglycans. *Arteriosclerosis* 9: 1-20.
4. Kjellen, L., and Lindahl, U. (1991). Proteoglycans: structures and interactions. *Annu. Rev. Biochem.* 60: 443-475.
5. Ruoslahti, E., and Yamaguchi, Y. (1991). Proteoglycans as modulators of growth factor activities. *Cell* 64: 867-869.
6. Vlodavsky, I., Bar-Shavit, R., Korner, G., and Fuks, Z. (1993). Extracellular matrix-bound growth factors, enzymes and plasma proteins. In *Basement membranes: Cellular and molecular aspects* (eds. D.H. Rohrbach and R. Timpl), pp 327-343. Academic press Inc., Orlando, Fl.
7. Vlodavsky, I., Eldor, A., Haimovitz-Friedman, A., Matzner, Y., Ishai-Michaeli, R., Levi, E., Bashkin, P., Lider, O., Naparstek, Y., Cohen, I.R., and Fuks, Z. (1992). Expression of heparanase by platelets and circulating cells of the immune system: Possible involvement in diapedesis and extravasation. *Invasion & Metastasis* 12: 112-127.
8. Vlodavsky, I., Mohsen, M., Lider, O., Ishai-Michaeli, R., Ekre, H.-P., Svahn, C.M., Vigoda, M., and Peretz, T. (1995). Inhibition of tumor metastasis by heparanase inhibiting species of heparin. *Invasion & Metastasis* 14: 290-302.
9. Nakajima, M., Irimura, T., and Nicolson, G.L. (1988). Heparanase and tumor metastasis. *J. Cell. Biochem.* 36: 157-167.

10. Liotta, L.A., Rao, C.N., and Barsky, S.H. (1983). Tumor invasion and the extracellular matrix. *Lab. Invest.* 49: 639-649.
11. Vlodavsky, I., Fuks, Z., Bar-Ner, M., Ariav, Y., and Schirmacher, V. (1983). Lymphoma cell mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. *Cancer Res.* 43: 2704-2711.
12. Vlodavsky, I., Ishai-Michaeli, R., Bar-Ner, M., Fridman, R., Horowitz, A.T., Fuks, Z. and Biran, S. (1988). Involvement of heparanase in tumor metastasis and angiogenesis. *Is. J. Med.* 24: 464-470.
13. Parish, C.R., Coombe, D.R., Jakobsen, K.B., and Underwood, P.A. (1987). Evidence that sulphated polysaccharides inhibit tumor metastasis by blocking tumor cell-derived heparanase. *Int. J. Cancer* 40: 511-517.
14. Vlodavsky, I., Liu, G.M., and Gospodarowicz, D. (1980). Morphological appearance, growth behavior and migratory activity of human tumor cells maintained on extracellular matrix vs. plastic. *Cell* 19: 607-616.
15. Gospodarowicz, D., Delgado, D., and Vlodavsky, I. (1980). Permissive effect of the extracellular matrix on cell proliferation in-vitro. *Proc. Natl. Acad. Sci. USA* 77: 4094-4098.
16. Burgess, W.H., and Maciag, T. (1989). The heparin-binding (fibroblast) growth factor family of proteins. *Annu. Rev. Biochem.* 58: 575-606.
17. Folkman, J., and Klagsbrun, M. (1987). Angiogenic factors. *Science* 235: 442-447.
18. Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., Bashkin, P., and Fuks, Z. (1991). Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? *Trends Biochem. Sci.* 16: 268-271.

19. Cardon-Cardo, C., Vlodavsky, I., Haimovitz-Friedman, A., Hicklin, D., and Fuks, Z. (1990). Expression of basic fibroblast growth factor in normal human tissues. *Lab. Invest.* 63: 832-840.
20. Ishai-Michaeli, R., Eldor, A., and Vlodavsky, I. (1990). Heparanase activity expressed by platelets, neutrophils and lymphoma cells releases active fibroblast growth factor from extracellular matrix. *Cell Reg.* 1: 833-842.
21. Campbell, K.H., Rennick, R.E., Kalevich, S.G., and Campbell, G.R. (1992) *Exp. Cell Res.* 200: 156-167.
22. Oosta, G.M., Favreau, L.V., Beeler, D.L., and Rosenberg, R.D. (1982) Purification and properties of human platelets heparitinase. *J. Biol. Chem.* 257: 11,249-11,255.
23. Hoogewerf, A.J., Leone, J.W., Reardon, M., Howe, W.J., Asa, D., Heinrichson, R.L., and Ledbetter, S.R. (1995). CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. *J. Biol. Chem.* 270: 3268-3277.
24. Freeman, C., and Parish, C.R. (1988). Human platelet heparanase: Purification, characterization and catalytic activity. *Biochem. J.* 330:1341-1350.
25. Goshen, R., Hochberg, A., Korner, G., Levi, E., Ishai-Michaeli, R., Elkin, M., de Grot, N., and Vlodavsky, I. (1996) Purification and characterization of placental heparanase and its expression by cultured cytotrophoblasts. *Mol. Human Reprod.* 2: 679-684.
26. Jin, L., Nakajima, M. and Nicolson, G.L. (1990). Immunochemical localization of heparanase in mouse and human melanoma. *Int. J. Cancer* 45: 1088-1095.
- 26a. Mollinedo, F., Naagima, M., Leorens, A., Barbosa, e., Callejo, S., Gajate, C. and Fabras, a. (1997) Major co-localization of the

extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils. *Biochem. J.* 327:917-923.

27. De Vouge, M.W., Yamazaki, A., Bennett, S.A.L., Chen, J.-H., Shwed, P.S., Couture, C., and Birnboim, H.C. (1994). Immuno selection of GRP94/endoplasmic reticulum protein from a KNRK cell specific λ gt11 library using antibodies directed against a putative heparanase amino terminal peptide. *Int. J. Cancer* 56: 286-294.

28. Graham, L.D., and Underwood, P.A. (1996) Comparison of the heparanase enzyme from mouse melanoma cells, mouse macrophages and human platelets. *Biochem. and Mol. Biol. International* 39: 563-571.

29. Kosir, M. A., Quinn, C. C. V., Zukowski, K. L., Grignon, D. J., and Ledbetter, S. (1997) *J. Surg. Res.* 67: 98-105.

30. Kosir, M. A., Quinn, C. C. V., Pandey P., Berzinskas-Weller, E., Ledbetter, S. Fridman, R., and Wisscher, D. (1996) *Cancer Res.* 37: 495 (Ab. # 3378).

30a. Ernst, S., Langer, R., Cooney, Ch.L., and Sasisekharan, R. (1995) Enzymatic degradation of glycosaminoglycans. *Critical Reviews in Biochemistry and Molecular Biology*: 30(5): 387-444.

31. Gospodarowicz, D., Mescher, A.L., Birdwell, C.R. (1977). Stimulation of corneal endothelial cell proliferation in vitro by fibroblast and epidermal growth factors. *Exp Eye Res* 25: 75-89.

32. Haimovitz-Friedman, A., Falcone, D.J., Eldor, A., Schirmacher, V., Vlodavsky, I., and Fuks, Z. (1991). Activation of platelet heparitinase by tumor cell derived factors. *Blood* 78: 789-796.

33. Yelton, D.E., Scharff, M.D. (1981). Monoclonal antibodies: a powerful new tool in biology and medicine. *Annu. Rev. Biochem.* 50: 657-680.

34. Friedmann, Y. and Daniel, C.W. (1996). Regulated expression of homeobox genes *Msx-1* and *Msx-2* in the mouse mammary gland

suggests a role in epithelial-stromal interactions, hormone action and neoplasia. *Devel. Biol.* 177: 347-355.

35. Soule, H. D., Maloney, T. M., Wolman, S. R., Peterson, W. D., et al. (1990) *Cancer Res.* 50: 6075-6086.

36. Mill, F. R., Soul, H. D., Tait, L., Pauley, R. J., Wolman, S.R., Dawson, P. J., and Heppner, G. H. (1993) *J. Nat. Cancer Inst.* 85: 1725-1732.

37. Nakajima, M., Irimura, T., Di Ferrante, D., DiFerrante, N. and Nicolson, G.L. (1983) Heparan sulfate degradation: relation to tumor invasion and metastatic properties of mouse B16 melanoma sublines. *Science* 220: 611-613.

38. The Genesis report. (1996, 1997).

39. Iscove NN, Melchers F. Complete replacement of serum by albumin, transferrin, and soybean lipid in cultures of lipopolysaccharide-reactive B lymphocytes. *J. Exp. Med.* 147: 923-933.

40. Bjorck L, Kronvall G. Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. *J. Immunol* 1984; 133: 969-974.

WHAT IS CLAIMED IS:

1. A method of *in situ* detecting localization and distribution of heparanase expression in a biological sample comprising the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting the localization and distribution of said detectable heparanase specific molecular probe.
2. The method of claim 1, wherein said biological sample is selected from the group consisting of cells and tissues.
3. The method of claim 1, wherein said biological sample is malignant.
4. The method of claim 3, wherein said malignancy is selected from the group consisting of a solid tumor and a hematopoietic tumor.
5. The method of claim 4, wherein said solid tumor is selected from the group consisting of carcinoma, adenocarcinoma, squamous cell carcinoma, teratocarcinoma, mesothelioma and melanoma, and further wherein said hematopoietic tumor is selected from the group consisting of lymphoma and leukemia.
6. The method of claim 4, wherein said solid tumor is a primary tumor, or a metastasis thereof, and is originated from an organ selected from the group consisting of liver, prostate, bladder, breast, ovary, cervix, colon, skin, intestine, stomach, uterus, pancreas.
7. The method of claim 1, wherein said detectable heparanase specific molecular probe is selected from the group consisting of a nucleic acid sequence hybridizable with heparanase encoding nucleic acid and an anti-heparanase antibody capable of specifically binding heparanase.
8. The method of claim 7, wherein said nucleic acid sequence hybridizable with heparanase encoding nucleic acid is selected from the group consisting of a synthetic oligonucleotide, an antisense heparanase RNA and heparanase DNA, labeled by a detectable moiety.

9. A method of detecting heparanase protein in a body fluid of a patient comprising the steps of reacting said body fluid with an anti-heparanase antibody and monitoring said reaction.

10. The method of claim 9, wherein said body fluid is selected from the group consisting of plasma, urine, pleural effusions and saliva.

11. The method of claim 9, wherein said body fluid is of a patient suffering from a condition selected from the group consisting of cancer, renal disease, diabetes and inflammation.

12. The method of claim 11, wherein said renal disease is associated with diabetes.

13. The method of claim 9, wherein said anti-heparanase antibody is selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

14. The method of claim 9, wherein reacting said body fluid with said anti-heparanase antibody is effected in solution.

15. The method of claim 9, wherein reacting said body fluid with said anti-heparanase antibody is effected on a substrate capable of adsorbing proteins present in said body fluid.

16. The method of claim 9, wherein said body fluid is of a patient suffering from myeloma, breast carcinoma, metastatic breast carcinoma, hemorrhagic nephritis, nephrotic syndrome, normoalbuminuric type I diabetes, microalbuminuric type I diabetes, kidney disorder, inflammation, sepsis, inflammatory and autoimmune disease.

17. A method of detecting the presence, absence or level of heparanase transcripts in a biological sample comprising the steps of:

- (a) extracting messenger RNA from the biological sample, thereby obtaining a plurality of messenger RNAs;
- (b) reverse transcribing said plurality of messenger RNAs into a plurality of complementary DNAs;

- (c) contacting said plurality of complementary DNAs with a pair of heparanase specific polymerase chain reaction primers, nucleoside triphosphates and a thermostable DNA polymerase;
- (d) performing a polymerase chain reaction; and
- (e) detecting the presence, absence or level of said polymerase chain reaction product.

18. A method of detecting heparanase messenger RNA in a biological sample comprising the steps of reverse transcribing the messenger RNA into complementary DNA, contacting said complementary DNA with polymerase chain reaction oligonucleotides hybridizable to heparanase encoding nucleic acid, performing a polymerase chain reaction and monitoring for heparanase specific polymerase chain reaction products.

19. A method of detecting the presence, absence or level of heparanase protein in a biological sample comprising the steps of:

- (a) extracting proteins from the biological sample, thereby obtaining a plurality of proteins;
- (b) size separating said proteins;
- (c) interacting said size separated proteins with an anti-heparanase antibody; and
- (d) detecting the presence, absence or level of said interacted anti-heparanase antibody.

20. The method of claim 19, wherein said anti-heparanase antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.

21. The method of claim 19, wherein said size separation is effected by electrophoresis.

22. A method of targeted drug delivery to a tissue of a patient, the tissue expressing heparanase, the method comprising the steps of providing a complex of a drug directly or indirectly linked to an anti-heparanase antibody and administering said complex to the patient.

23. A method of treating a patient having a condition associated with heparanase expression comprising the step of administering an anti-heparanase antibody to the patient.

24. An antibody elicited by a heparanase protein or an immunogenical portion thereof, the antibody specifically binds heparanase.

25. The antibody of claim 24, wherein said heparanase protein is recombinant.

26. The antibody of claim 24, wherein said elicitation is through *in vivo* or *in vitro* techniques, said antibody having been prepared by a process comprising the steps of:

- (a) exposing cells capable of producing antibodies to said heparanase protein or said immunogenical part thereof and thereby generating antibody producing cells;
- (b) fusing said antibody producing cells with myeloma cells and thereby generating a plurality of hybridoma cells each producing monoclonal antibodies; and
- (c) screening said plurality of monoclonal antibodies to identify a monoclonal antibody which specifically binds heparanase.

27. The antibody of claim 24, wherein the antibody is selected from the group consisting of a polyclonal antibody and a monoclonal antibody.

28. The antibody of claim 27, wherein said polyclonal antibody is selected from the group consisting of a crude polyclonal antibody and an affinity purified polyclonal antibody.

29. An oligonucleotide comprising a nucleic acid sequence specifically hybridizable with heparanase encoding nucleic acid.

30. An antisense nucleic acid molecule comprising a nucleic acid sequence specifically hybridizable with heparanase messenger RNA.

31. A sense nucleic acid molecule comprising a nucleic acid sequence specifically hybridizable with heparanase antisense RNA.

32. A pair of polymerase chain reaction primers comprising a sense primer and an antisense primers, each of said primers including a nucleic acid sequence specifically hybridizable with heparanase encoding nucleic acid.

33. The use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression.

34. The use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase.

35. The use of a heparanase specific molecular probe for quantification of heparanase in a body fluid.

36. The use of a heparanase specific molecular probe for targeted drug delivery.

37. The use of a heparanase specific molecular probe as a therapeutic agent.

38. A method of detecting heparanase expression in a biological sample comprising the step of reacting the biological sample with a detectable heparanase specific molecular probe and detecting said detectable heparanase specific molecular probe.

FIG. 1




FIG. 2A





FIG. 2B








FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 7




FIG. 8A





FIG. 8B






FIG. 11B

FIG. 11D

FIG. 11F




FIG. 11A

FIG. 11C

FIG. 11E

FIG. 12B

FIG. 12C

FIG. 12F




FIG. 12A

FIG. 12C

FIG. 12E




FIG. 13A




FIG. 13B




FIG. 14




FIG. 15




Fig. 16b




Fig. 16c




Fig. 16d








Fig. 16e

Data from "401"






FIG. 17A




FIG. 17B




FIG. 18




FIG. 19A




FIG. 19B




FIG. 20




FIG. 21A

FIG. 21B



FIG. 22B

FIG. 22A




FIG. 23A

FIG. 23B

FIG. 23C

FIG. 24





FIG. 25






FIG. 26

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANTS: Iris Pecker et al.
- (ii) TITLE OF INVENTION: HEPARANASE SPECIFIC MOLECULAR PROBES
AND THEIR USE IN RESEARCH AND MEDICAL
APPLICATIONS
- (iii) NUMBER OF SEQUENCES: 7
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Mark M. Friedman c/o Anthony Castorina
- (B) STREET: 20001 Jefferson Davis Highway, Suite 207
- (C) CITY: Arlington
- (D) STATE: Virginia
- (E) COUNTRY: United States of America
- (F) ZIP: 22202
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 1.44 megabyte, 3.5" microdisk
- (B) COMPUTER: Twinhead® Slimnote-890TX
- (C) OPERATING SYSTEM: MS DOS version 6.2,
Windows version 3.11
- (D) SOFTWARE: Word for Windows version 2.0 converted to
an ASCII file
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) APPLICATION NUMBER:
- (D) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Friedman, Mark M.
- (B) REGISTRATION NUMBER: 33,883
- (C) REFERENCE/DOCKET NUMBER: 910/5
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: 972-3-5625553
- (B) TELEFAX: 972-3-5625554
- (C) TELEX:
- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1721
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- CTAGAGCTTT CGACTCTCCG CTGCGCGGCA GCTGGCGGGG GGAGCAGCCA GGTGAGCCCA 60
- AGATGCTGCT GCGCTCGAAG CCTGCGCTGC CGCCGCCGCT GATGCTGCTG CTCCTGGGGC 120
- CGCTGGGTCC CCTCTCCCTT GCGGCCCTGC CCCGACCTGC GCAAGCACAG GACGTCGTGG 180
- ACCTGGACTT cTTACCCAG GAGCCGCTGC ACCTGGTGAG CCCCTCGTTC CTGTCCGTCA 240
- CCATTGACGC CAACCTGGCC ACGGACCGC GGTTCCTCAT CCTCCTGGGT TCTCCAAAGC 300
- TTCTGACCTT GGCCAGAGGC TTGTCTCCTG CGTACCTGAG GTTGTGTGGC ACCAAGACAG 360
- ACTTCCTAAT TTTCGATCCC AAGAAGGAAT CAACCTTTGA AGAGAGAAGT TACTGGCAAT 420
- CTCAAGTCAA CCAGGATATT TGCAAATATG GATCCATCCC TCCTGATGTG GAGGAGAAGT 480
- TACGGTTGGA ATGGCCCTAC CAGGAGCAAT TGCTACTCCG AGAACACTAC CAGAAAAAGT 540
- TCAAGAACAG CACCTACTCA AGAAGCTCTG TAGATGTGCT ATACACTTTT GCAAAGTCT 600
- CAGGACTGGA CTGTATCTTT GGCCTAAATG CGTTATTAAG AACAGCAGAT TTGCAGTGGA 660
- ACAGTTCTAA TGCTCAGTTG CTCCTGGACT ACTGCTCTTC CAAGGGGTAT AACATTCTT 720
- GGGAACTAGG CAATGAACCT AACAGTTTCC TTAAGAAGGC TGATATTTTC ATCAATGGGT 780
- CGCAGTTAGG AGAAGATTAT ATTCAATTGC ATAACTTCT AAGAAAGTCC ACCTTCAAAA 840
- ATGCAAAACT CTATGTGCTT GATGTTGGTC AGCCTCGAAG AAAGACGGCT AAGATGCTGA 900

5 AGAGCTTCCT GAAGGCTGGT GGAGAAGTGA TTGATTCAGT TACATGGCAT CACTACTATT 960
 TGAATGGACG GACTGCTACC AGGGAAGATT TTCTAAACCC TGATGTATTG GACATTTTAA 1020
 TTTTCATCTGT GCAAAAAGTT TTCCAGGTGG TTGAGAGCAC CAGGCCTGGC AAGAAGGTCT 1080
 GGTTAGGAGA AACAAGCTCT GCATATGGAG GCGGAGCGCC CTTGCTATCC GACACCTTTG 1140
 CAGCTGGCTT TATGTGGCTG GATAAATTGG GCCTGTCAGC CCGAATGGGA ATAGAAGTGG 1200
 10 TGATGAGGCA AGTATTCTTT GGAGCAGGAA ACTACCATTT AGTGGATGAA AACTTCGATC 1260
 CTTTACCTGA TTATTGGCTA TCTCTTCTGT TCAAGAAATT GGTGGGCACC AAGGTGTTAA 1320
 TGGCAAGCGT GCAAGGTTCA AAGAGAAGGA AGCTTCGAGT ATACCTTCAT TGCACAAACA 1380
 CTGACAATCC AAGGTATAAA GAAGGAGATT TAACTCTGTA TGCCATAAAC CTCCATAACG 1440
 15 TCACCAAGTA CTTGCGGTTA CCCTATCCTT TTTCTAACAA GCAAGTGGAT AAATACCTTC 1500
 TAAGACCTTT GGGACCTCAT GGATTACTTT CCAATCTGT CCAACTCAAT GGTCTAACTC 1560
 TAAAGATGGT GGATGATCAA ACCTTGCCAC CTTTAATGGA AAAACCTCTC CGGCCAGGAA 1620
 GTTCACTGGG CTTGCCAGCT TTTCATATA GTTTTTTGT GATAAGAAAT GCCAAAGTTG 1680
 CTGCTTGCAT CTGAAAATAA AATATACTAG TCCTGACACT G 1721

(2) INFORMATION FOR SEQ ID NO:2:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 543
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

25 Met Leu Leu Arg Ser Lys Pro Ala Leu Pro Pro Pro Leu Met Leu Leu
 5 10 15
 Leu Leu Gly Pro Leu Gly Pro Leu Ser Pro Gly Ala Leu Pro Arg Pro
 20 25 30
 30 Ala Gln Ala Gln Asp Val Val Asp Leu Asp Phe Phe Thr Gln Glu Pro
 35 40 45
 Leu His Leu Val Ser Pro Ser Phe Leu Ser Val Thr Ile Asp Ala Asn
 50 55 60
 35 Leu Ala Thr Asp Pro Arg Phe Leu Ile Leu Leu Gly Ser Pro Lys Leu
 65 70 75 80
 40 Arg Thr Leu Ala Arg Gly Leu Ser Pro Ala Tyr Leu Arg Phe Gly Gly
 85 90 95
 Thr Lys Thr Asp Phe Leu Ile Phe Asp Pro Lys Lys Glu Ser Thr Phe
 100 105 110
 45 Glu Glu Arg Ser Tyr Trp Gln Ser Gln Val Asn Gln Asp Ile Cys Lys
 115 120 125
 Tyr Gly Ser Ile Pro Pro Asp Val Glu Glu Lys Leu Arg Leu Glu Trp
 130 135 140
 50 Pro Tyr Gln Glu Gln Leu Leu Leu Arg Glu His Tyr Gln Lys Lys Phe
 145 150 155 160
 Lys Asn Ser Thr Tyr Ser Arg Ser Ser Val Asp Val Leu Tyr Thr Phe
 165 170 175
 55 Ala Asn Cys Ser Gly Leu Asp Leu Ile Phe Gly Leu Asn Ala Leu Leu
 180 185 190
 60 Arg Thr Ala Asp Leu Gln Trp Asn Ser Ser Asn Ala Gln Leu Leu Leu
 195 200 205
 Asp Tyr Cys Ser Ser Lys Gly Tyr Asn Ile Ser Trp Glu Leu Gly Asn
 210 215 220
 65 Glu Pro Asn Ser Phe Leu Lys Lys Ala Asp Ile Phe Ile Asn Gly Ser
 225 230 235 240
 Gln Leu Gly Glu Asp Tyr Ile Gln Leu His Lys Leu Leu Arg Lys Ser
 245 250 255
 70 Thr Phe Lys Asn Ala Lys Leu Tyr Gly Pro Asp Val Gly Gln Pro Arg
 260 265 270
 75 Arg Lys Thr Ala Lys Met Leu Lys Ser Phe Leu Lys Ala Gly Gly Glu

275 280 285

Val Ile Asp Ser Val Thr Trp His His Tyr Tyr Leu Asn Gly Arg Thr
290 295 300

5 Ala Thr Arg Glu Asp Phe Leu Asn Pro Asp Val Leu Asp Ile Phe Ile
305 310 315 320

10 Ser Ser Val Gln Lys Val Phe Gln Val Val Glu Ser Thr Arg Pro Gly
325 330 335

Lys Lys Val Trp Leu Gly Glu Thr Ser Ser Ala Tyr Gly Gly Gly Ala
340 345 350

15 Pro Leu Leu Ser Asp Thr Phe Ala Ala Gly Phe Met Trp Leu Asp Lys
355 360 365

Leu Gly Leu Ser Ala Arg Met Gly Ile Glu Val Val Met Arg Gln Val
370 375 380

20 Phe Phe Gly Ala Gly Asn Tyr His Leu Val Asp Glu Asn Phe Asp Pro
385 390 395 400

25 Leu Pro Asp Tyr Trp Leu Ser Leu Leu Phe Lys Lys Leu Val Gly Thr
405 410 415

Lys Val Leu Met Ala Ser Val Gln Gly Ser Lys Arg Arg Lys Leu Arg
420 425 430

30 Val Tyr Leu His Cys Thr Asn Thr Asp Asn Pro Arg Tyr Lys Glu Gly
435 440 445

Asp Leu Thr Leu Tyr Ala Ile Asn Leu His Asn Val Thr Lys Tyr Leu
450 455 460

35 Arg Leu Pro Tyr Pro Phe Ser Asn Lys Gln Val Asp Lys Tyr Leu Leu
465 470 475 480

40 Arg Pro Leu Gly Pro His Gly Leu Leu Ser Lys Ser Val Gln Leu Asn
485 490 495

Gly Leu Thr Leu Lys Met Val Asp Asp Gln Thr Leu Pro Pro Leu Met
500 505 510

45 Glu Lys Pro Leu Arg Pro Gly Ser Ser Leu Gly Leu Pro Ala Phe Ser
515 520 525

Tyr Ser Phe Phe Val Ile Arg Asn Ala Lys Val Ala Ala Cys Ile
530 535 540 543

50 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1721
(B) TYPE: Nucleic acid
(C) STRANDEDNESS: Double
(D) TOPOLOGY: linear
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

55

60 CT AGA GCT TTC GAC 14

TCT CCG CTG CGC GGC AGC TGG CGG GGG GAG CAG CCA GGT GAG CCC AAG 62

ATG CTG CTG CGC TCG AAG CCT GCG CTG CCG CCG CCG CTG ATG CTG CTG 110
Met Leu Leu Arg Ser Lys Pro Ala Leu Pro Pro Pro Leu Met Leu Leu 15

65 CTC CTG GGG CCG CTG GGT CCC CTC TCC CCT GGC GCC CTG CCC CGA CCT 158
Leu Leu Gly Pro Leu Gly Pro Leu Ser Pro Gly Ala Leu Pro Arg Pro 20 25 30

70 GCG CAA GCA CAG GAC GTC GTG GAC CTG GAC TTC TTC ACC CAG GAG CCG 206
Ala Gln Ala Gln Asp Val Val Asp Leu Asp Phe Phe Thr Gln Glu Pro 35 40 45

75 CTG CAC CTG GTG AGC CCC TCG TTC CTG TCC GTC ACC ATT GAC GCC AAC 254

	Leu	His	Leu	Val	Ser	Pro	Ser	Phe	Leu	Ser	Val	Thr	Ile	Asp	Ala	Asn	
	50						55					60					
5	CTG	GCC	ACG	GAC	CCG	CGG	TTC	CTC	ATC	CTC	CTG	GGT	TCT	CCA	AAG	CTT	302
	Leu	Ala	Thr	Asp	Pro	Arg	Phe	Leu	Ile	Leu	Leu	Gly	Ser	Pro	Lys	Leu	
	65					70					75					80	
10	CGT	ACC	TTG	GCC	AGA	GGC	TTG	TCT	CCT	GCG	TAC	CTG	AGG	TTT	GGT	GGC	350
	Arg	Thr	Leu	Ala	Arg	Gly	Leu	Ser	Pro	Ala	Tyr	Leu	Arg	Phe	Gly	Gly	
					85				90					95			
15	ACC	AAG	ACA	GAC	TTC	CTA	ATT	TTC	GAT	CCC	AAG	AAG	GAA	TCA	ACC	TTT	398
	Thr	Lys	Thr	Asp	Phe	Leu	Ile	Phe	Asp	Pro	Lys	Lys	Glu	Ser	Thr	Phe	
				100				105					110				
20	GAA	GAG	AGA	AGT	TAC	TGG	CAA	TCT	CAA	GTC	AAC	CAG	GAT	ATT	TGC	AAA	446
	Glu	Glu	Arg	Ser	Tyr	Trp	Gln	Ser	Gln	Val	Asn	Gln	Asp	Ile	Cys	Lys	
			115				120					125					
25	TAT	GGA	TCC	ATC	CCT	CCT	GAT	GTG	GAG	GAG	AAG	TTA	CGG	TTG	GAA	TGG	494
	Tyr	Gly	Ser	Ile	Pro	Pro	Asp	Val	Glu	Glu	Lys	Leu	Arg	Leu	Glu	Trp	
	130					135						140					
30	CCC	TAC	CAG	GAG	CAA	TTG	CTA	CTC	CGA	GAA	CAC	TAC	CAG	AAA	AAG	TTC	542
	Pro	Tyr	Gln	Glu	Gln	Leu	Leu	Leu	Arg	Glu	His	Tyr	Gln	Lys	Lys	Phe	
	145					150					155					160	
35	AAG	AAC	AGC	ACC	TAC	TCA	AGA	AGC	TCT	GTA	GAT	GTG	CTA	TAC	ACT	TTT	590
	Lys	Asn	Ser	Thr	Tyr	Ser	Arg	Ser	Ser	Val	Asp	Val	Leu	Tyr	Thr	Phe	
				165				170						175			
40	GCA	AAC	TGC	TCA	GGA	CTG	GAC	TTG	ATC	TTT	GGC	CTA	AAT	GCG	TTA	TTA	638
	Ala	Asn	Cys	Ser	Gly	Leu	Asp	Leu	Ile	Phe	Gly	Leu	Asn	Ala	Leu	Leu	
				180				185					190				
45	AGA	ACA	GCA	GAT	TTG	CAG	TGG	AAC	AGT	TCT	AAT	GCT	CAG	TTG	CTC	CTG	686
	Arg	Thr	Ala	Asp	Leu	Gln	Trp	Asn	Ser	Ser	Asn	Ala	Gln	Leu	Leu	Leu	
			195				200					205					
50	GAC	TAC	TGC	TCT	TCC	AAG	GGG	TAT	AAC	ATT	TCT	TGG	GAA	CTA	GGC	AAT	734
	Asp	Tyr	Cys	Ser	Ser	Lys	Gly	Tyr	Asn	Ile	Ser	Trp	Glu	Leu	Gly	Asn	
	210					215						220					
55	GAA	CCT	AAC	AGT	TTC	CTT	AAG	AAG	GCT	GAT	ATT	TTC	ATC	AAT	GGG	TCG	782
	Glu	Pro	Asn	Ser	Phe	Leu	Lys	Lys	Ala	Asp	Ile	Phe	Ile	Asn	Gly	Ser	
	225					230					235				240		
60	CAG	TTA	GGA	GAA	GAT	TAT	ATT	CAA	TTG	CAT	AAA	CTT	CTA	AGA	AAG	TCC	830
	Gln	Leu	Gly	Glu	Asp	Tyr	Ile	Gln	Leu	His	Lys	Leu	Leu	Arg	Lys	Ser	
				245				250						255			
65	ACC	TTC	AAA	AAT	GCA	AAA	CTC	TAT	GGT	CCT	GAT	GTT	GGT	CAG	CCT	CGA	878
	Thr	Phe	Lys	Asn	Ala	Lys	Leu	Tyr	Gly	Pro	Asp	Val	Gly	Gln	Pro	Arg	
				260				265					270				
70	AGA	AAG	ACG	GCT	AAG	ATG	CTG	AAG	AGC	TTC	CTG	AAG	GCT	GGT	GGA	GAA	926
	Arg	Lys	Thr	Ala	Lys	Met	Leu	Lys	Ser	Phe	Leu	Lys	Ala	Gly	Gly	Glu	
			275				280					285					
75	GTG	ATT	GAT	TCA	GTT	ACA	TGG	CAT	CAC	TAC	TAT	TTG	AAT	GGA	CGG	ACT	974
	Val	Ile	Asp	Ser	Val	Thr	Trp	His	His	Tyr	Tyr	Leu	Asn	Gly	Arg	Thr	
	290					295						300					
80	GCT	ACC	AGG	GAA	GAT	TTT	CTA	AAC	CCT	GAT	GTA	TTG	GAC	ATT	TTT	ATT	1022
	Ala	Thr	Arg	Glu	Asp	Phe	Leu	Asn	Pro	Asp	Val	Leu	Asp	Ile	Phe	Ile	
	305					310					315				320		
85	TCA	TCT	GTG	CAA	AAA	GTT	TTC	CAG	GTG	GTT	GAG	AGC	ACC	AGG	CCT	GGC	1070
	Ser	Ser	Val	Gln	Lys	Val	Phe	Gln	Val	Val	Glu	Ser	Thr	Arg	Pro	Gly	
				325				330					335				
90	AAG	AAG	GTC	TGG	TTA	GGA	GAA	ACA	AGC	TCT	GCA	TAT	GGA	GGC	GGA	GCG	1118
	Lys	Lys	Val	Trp	Leu	Gly	Glu	Thr	Ser	Ser	Ala	Tyr	Gly	Gly	Gly	Ala	
				340				345					350				

CCC TTG CTA TCC GAC ACC TTT GCA GCT GGC TTT ATG TGG CTG GAT AAA 1166
 Pro Leu Leu Ser Asp Thr Phe Ala Ala Gly Phe Met Trp Leu Asp Lys
 355 360 365

5 TTG GGC CTG TCA GCC CGA ATG GGA ATA GAA GTG GTG ATG AGG CAA GTA 1214
 Leu Gly Leu Ser Ala Arg Met Gly Ile Glu Val Val Met Arg Gln Val
 370 375 380

10 TTC TTT GGA GCA GGA AAC TAC CAT TTA GTG GAT GAA AAC TTC GAT CCT 1262
 Phe Phe Gly Ala Gly Asn Tyr His Leu Val Asp Glu Asn Phe Asp Pro
 385 390 395 400

15 TTA CCT GAT TAT TGG CTA TCT CTT CTG TTC AAG AAA TTG GTG GGC ACC 1310
 Leu Pro Asp Tyr Trp Leu Ser Leu Leu Phe Lys Lys Leu Val Gly Thr
 405 410 415

20 AAG GTG TTA ATG GCA AGC GTG CAA GGT TCA AAG AGA AGG AAG CTT CGA 1358
 Lys Val Leu Met Ala Ser Val Gln Gly Ser Lys Arg Arg Lys Leu Arg
 420 425 430

25 GTA TAC CTT CAT TGC ACA AAC ACT GAC AAT CCA AGG TAT AAA GAA GGA 1406
 Val Tyr Leu His Cys Thr Asn Thr Asp Asn Pro Arg Tyr Lys Glu Gly
 435 440 445

30 GAT TTA ACT CTG TAT GCC ATA AAC CTC CAT AAC GTC ACC AAG TAC TTG 1454
 Asp Leu Thr Leu Tyr Ala Ile Asn Leu His Asn Val Thr Lys Tyr Leu
 450 455 460

35 CGG TTA CCC TAT CCT TTT TCT AAC AAG CAA GTG GAT AAA TAC CTT CTA 1502
 Arg Leu Pro Tyr Pro Phe Ser Asn Lys Gln Val Asp Lys Tyr Leu Leu
 465 470 475 480

40 AGA CCT TTG GGA CCT CAT GGA TTA CTT TCC AAA TCT GTC CAA CTC AAT 1550
 Arg Pro Leu Gly Pro His Gly Leu Leu Ser Lys Ser Val Gln Leu Asn
 485 490 495

45 GGT CTA ACT CTA AAG ATG GTG GAT GAT CAA ACC TTG CCA CCT TTA ATG 1598
 Gly Leu Thr Leu Lys Met Val Asp Asp Gln Thr Leu Pro Pro Leu Met
 500 505 510

50 GAA AAA CCT CTC CGG CCA GGA AGT TCA CTG GGC TTG CCA GCT TTC TCA 1646
 Glu Lys Pro Leu Arg Pro Gly Ser Ser Leu Gly Leu Pro Ala Phe Ser
 515 520 525

55 TAT AGT TTT TTT GTG ATA AGA AAT GCC AAA GTT GCT GCT TGC ATC TGA 1694
 Tyr Ser Phe Phe Val Ile Arg Asn Ala Lys Val Ala Ala Cys Ile
 530 535 540 543

60 AAA TAA AAT ATA CTA GTC CTG ACA CTG 1721

(2) INFORMATION FOR SEQ ID NO:4:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
 CGCATATGCA GGACGTCGTG GACCTG 26

65 (2) INFORMATION FOR SEQ ID NO:5:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
 TATGATCCTC TAGTACTTCT CGAC 24

70 (2) INFORMATION FOR SEQ ID NO:6:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 23
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 75 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTCGATCCCA AGAAGGAATC AAC 23

- (2) INFORMATION FOR SEQ ID NO:7:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GTAGTGATGC CATGTAATC AATC 24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/09255

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 16/00, 16/40; G01N 33/53; C07H 21/02, 21/04; A61K 39/395

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JIN et al. Immunochemical localization of heparanase in mouse and human melanomas. Int. J. Cancer. 1990, Vol. 45, pages 1088-1095, entire document.	1-5, 19-21, 24-28, 33, 38
X	MOLLINEDO et al. Major co-localization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils. Biochem. J. 1997, Vol. 327, pages 917-923, entire document.	1-2, 7, 33, 38

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

03 AUGUST 1999

Date of mailing of the international search report

21 SEP 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARIANNE DIBRINO

Telephone No. (703) 308-0196

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRX

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/09255

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y --- X	US 5,362,641 A (FUKS et al.) 08 November 1994, see entire document, especially column 2, lines 27-49, column 5, lines 9-10, column 10, lines 20-33 and column 16, lines 33-38.	9-11, 13-14, 16, 17-18, 33-35, 37- 38 --- 24-28
Y	WO 88/01280 A1 (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 25 February 1988, see entire document, especially page 7, lines 35-36 and page 8, lines 1-12.	9-11, 13-14, 33- 35, 37-38
X --- Y	US 5,332,812 A (NICOLSON et al.) 26 July 1994, see entire document, especially column 11, lines 22-30.	24-28 --- 9-11, 13-14, 16, 22-23, 33-38
X --- Y	HOOGEWERF et al. Cxc chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes. J. Biol. Chem. 17 February 1995, Vol. 270, No. 7, pages 3268-3277, especially page 3269.	24-28 --- 9-11, 13-14, 33- 38
Y	MANIATIS et al. 'Extraction, purification, and analysis of mRNA from eukaryotic cells.' In: Molecular Cloning, A Laboratory Manual. United States: Cold Spring Harbor Laboratory. 1982, Chapter 6, pages 188-246.	7-8, 17-18, 29
Y	US 4,683,195 A (MULLIS et al.) 28 July 1987, see entire document	7-8, 17-18, 29
Y	SUGGS et al. Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for Human β 2-microglobulin. Proc. Natl. Acad. Sci. November 1981, Vol. 78, No. 11, pages 6613-6617, especially page 6613.	7-8, 17-18, 29
X	KOSIR et al. Human prostate carcinoma cells produce extracellular heparanase. J. Surg. Res. 1997, Vol. 67, pages 98-105, entire document.	1-4, 6-7, 19-20, 24-28
Y	US 5,656,595 A (SCHWEIGHOFFER et al.) 12 August 1997, see entire document, especially column 4, lines 39-50.	7-8, 29-32
Y	US 5,618,709 A (GEWIRTZ et al.) 08 April 1997, see entire document, especially columns 12 and 13.	7-8, 29-32
Y	ALBERTS et al. Molecular Biology of the Cell. New York: Garland Publishing, Inc. 1989, 2nd Edition, pages 195-196 and 598, entire document.	7-8, 29-32

INTERNATIONAL SEARCH REPORT**International application No.**
PCT/US99/09255**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,602,095 A (PASTAN et al.) 11 February 1997, see entire document, especially column 2, lines 21-23.	22, 36

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/09255

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/09255

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/178.1, 181.1; 435/4, 7.1, 7.21, 7.23, 7.4, 40.52; 514/885; 530/387.1, 388.1, 388.8, 388.85, 389.7, 413; 536/23.1, 23.5, 24.3, 24.33

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

424/178.1, 181.1; 435/4, 7.1, 7.21, 7.23, 7.4, 40.52; 514/885; 530/387.1, 388.1, 388.8, 388.85, 389.7, 413; 536/23.1, 23.5, 24.3, 24.33

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN(EMBASE, MEDLINE, BIOSIS), APS, heparanase, clone, detect, transcript, sense, antisense, quantification, drug delivery, targeted, therapeutic, Friedman, Perets, Pecker, Vlodavsky, fluid, renal, diabetes, inflammation, RNA, anti-heparanase, antibody, endoglycosidase, exoglycosidase, antisera, monoclonal

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

I. Group I, claims 1-21, 33-35 and 38, drawn to a method of detection of heparanase in a biological sample using a heparanase specific molecular probe which is an anti-heparanase antibody capable of specifically binding heparanase.

II. Group II, claims 1-18, 33-35 and 38, drawn to a method of detection of heparanase in a biological sample using a heparanase specific molecular probe which is a nucleic acid sequence hybridizable with heparanase encoding nucleic acids.

III. Group III, claims 22 and 36, drawn to a method of targeted drug delivery.

IV. Group IV, claims 23 and 37, drawn to a method of treatment using an anti-heparanase antibody.

V. Group V, claim 37, drawn to a method of treatment using a nucleic acid sequence hybridizable with heparanase encoding nucleic acids.

VI. Group VI, claims 24-28, drawn to an anti-heparanase antibody.

VII. Group VII, claims 29-32, drawn to nucleic acids.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The putative special technical feature linking Groups I-VII appears to be the heparanase specific molecular probes of Group VI or VII. However, U.S. Patent No. 5,362,641 or U.S. Patent No. 5,332,812 teaches a heparanase specific molecular probe, an anti-heparanase antibody. Therefore, the technical feature linking the inventions of Groups I-VII does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.